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Abstract 
In order to ascertain the effects of creatine monohydrate (CrlhO) supplementation on 
muscle mass and strength in older males, seventeen volunteers aged between sixty and 
eighty years were allocated to a creatine or a placebo group. Both groups took part in a 
tmining programme of the knee flexors and extensors of one leg only, consisting of knee 
flexion in a standing position and knee extension in a seated position. An adjustable, 
weighted cuff was used to provide resistance and subjects increased their weight reps and 
sets at their own discretion. The creatine group supplemented their training with CrH20 
starting with a loading phase of 15 g CrH20 per day for 14 days and 3 g per day for the 
following 1 0 weeks. The placebo group took an equivalent amount of dextrose. The study 
was performed in a double·blind fashion. 
Strength changes were assessed using isokinetic dynamometry. Both isokinetic and 
isometric strength were tested.lsokinetic tests were done at 60°, 180° and 240° per second 
and isometric tests at 45°, 60° and 75°. Endurance was measured at the end of each testing 
session by means of five sets of 15 repetitions concentric knee extension and flexion at a 
speed of 180°/sec with 30 s rest between sets. Dual·energy X-ray absorptiometry (DEXA) 
scans were used to quantify total body lean mass and fat mass as well as limb segment mass 
changes, these were taken before and after the protocol. Serum creatinine was tested in 
order to quantify creatine uptake. 
There were no significant changes in the amount of serum creatinine for either group, nor 
were there any significant changes in body composition. Significant differences were found 
ii 
to occur in isometric and isokinetic strength, for both groups as a result of tmining over 
time. Isometric strength showed a significant increase over time overall (p~O.OS), but there 
was no statistical significance shown for any of the groups in respect to the baseline values. 
Subjects supplemented with CrH20 showed significant increases in isokinetic strength at 
the two slower velocities compared to baseline values. Subjects' endurance improved with 
training and the Cr group improved more than the PI group despite a slightly lower training 
volume. 
The major findings of this study were that CrH20 supplementation improved muscle 
function when combined with resistance training, particularly for repeated bout maximal 
activity in older males. The implications of this study are that this type of 
supplementation/training programme is well tolerated and would prove suitable for the 
more frail elderly population as well as individuals suffering from muscular degenerative 
disorders. 
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CHAPTER ONE 
Introduction 
As people age they experience a decrease in muscle mass, strength and exercise 
performance. Wasting of muscle can lead to reduced mobility and increased risk of 
injury due to falls (Rawson et a!., 1999). Although loss of muscle mass can be 
ameliorated with regular physical activity (Fiatrone and Evans, 1993), older individuals 
are less likely to adopt and maintain a regular exercise programme (Shephard, 1998). 
Thus any additional means by which the reduction in muscle mass with ageing and 
inactivity can be slowed or reversed would have great potential for improving the health 
and well being of the elderly. A number of researchers have reported that, in young 
subjects, creatine (Cr) supplementation has a positive effect on muscle mass (Balsam, et 
al., 1993; Earnest eta!., 1995; Greenhaff et al., 1994), strength (Earnest et al., 1995; 
Vandenberge et al., 1997) and perfonnance of high-intensity exercise (Casey et at 1996; 
Earnest et at, 1995; Jacobs eta!., 1997). Few studies have looked at the benefits ofCr 
supplementation alone or combined with weight training in older adults (Bennon eta!., 
1998; Rawson et al., 1998; Rawson et a1, 2001; Chrusch et al., 2001). These studies 
have yielded less consistent findings than those using younger subjects. 
1.1 Background and Significance 
Ergogenic aids, (from the Greek phrase meaning 'work production' (Pepping, 1999)) 
such as Cr monohydrate, are readily available for use in the sporting community 
(Becque et al., 2000). Cr monohydr3te (CrH,O) is used by the athletic population 
because of its perceived ability to increase muscle mass and thereby improve 
performance in events where strength and power play a major contribution (Nelson et 
I 
al., 2001). Creatine (from the word 'kreas', being Greek for 'flesh' (Wyss & Kaddurah 
- Daouk, 2000)) was first discovered in 1835, by the French scientist Chevreul who 
found and extracted it from meat products (Waldron et al., 2002). Nearly one hundred 
years later Eggleton et at., (1927) characterised the intramuscular compound 
phosphocreatine (PCr). The importance of PCr was realised with the discovery of the 
creatine phosphokinase (CK) reaction by Lundsgaard in 1934 (Wyss & Schulze, 2002). 
One of the main reasons why athletes supplement their diets witit Cristo increase PCr 
stores (Prevost et al., 1997). The functional basis for this practice is that it leads to an 
increased intracellular buffering of hydrogen ions (H+) and an enhanced ability to 
regenerate adenosine triphosphate (ATP) during high intensity exercise (Harris ct al., 
1992). Possible alternative mechanisms for the ergogenic effects of Crl-bO 
supplementation include greater mitochondrial CK activity and enhanced skeletal 
muscle protein synthesis. These mechanisms positively affect the rate of ATP 
resynthesis improving recovery resulting in an improvement in muscular perfonnance 
(Schilling et al., 2001). 
Theoretically the individuals who would potentially gain the most benefit from Cr 
supplementation are those who have reduced muscle mass, or decreased intramuscular 
PCr levels. Two of these potential groups include the elderly (Rawson et al., 1999) and 
subjects with neuromuscular diseases (Walter et al., 1999). Any intervention which 
leads to an improvement in muscle mass and/or muscle PCr content in such individuals 
would be likely to have the effect of increasing their physical capacity for work. Unlike 
athletes, Cr supplementation for these populations is not aimed at improving athletic 
petfonnance, but the ability to carry out everyday tasks which most people take for 
granted, such as climbing a flight of stairs or moving a piece of furniture without help. 
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This may in tum facilitate an increase in their level of physical activity and further 
improve muscle strength, with additional cardiovascular health benefits. 
There is evidence to suggest that, in older individuals, levels of muscle PCr, serum Cr 
and muscle Cr are reduced, although considerable variation exists between individuals 
(Moller et a\., 1980). Older adults Jose muscle mass as a consequence of a reduction in 
both muscle fibre number and size. resulting in a loss of muscle strength (Aniansson et 
al., 1986). Chrusch et al., (2001) showed that adults over the age of fifty years 
improved their muscular perfonnance with a combination of Cr supplementation and 
training, the effects of which could be attributed to improved PCr resynthesis. 
Therefore, the present study aimed to detennine whether supplementation with CrHlO 
would lead to increased muscle mass and strength of knee extensors and flexors in 
males aged 60-80 years, undergoing a home-based resistance training program, 
compared to a placebo group. Given the potential beneficial effects of Cr 
supplementation on intramuscular phosphagens, the author a1so anticipated that those 
subjects ingesting Cr would show greater improvements in training volume over time, 
compared to a placebo control group. The study was canied out using males aged 
between 60 and 80 years. The subje-cts were tested at baseline for knee extensor and 
flexor strength and endurance, serum creatinine levels, limb segmental mass of each 
thigh and whole body mass. The participants were randomly allocated to either a CrH20 
or a placebo group. All subjects were given the same home based light training regimen 
for the extensors and flexors of one leg only. This created four subgroups, CrH20 and 
training (CIT), CrH20 and no training I,CrU), placebo and training (PIT) and placebo 
and no training (PlU). The training inteiVention period was 12 weeks. Strength and 
endurance retests were carried out at weeks 2. 7 and 12. Body composition analysis and 
plasma creatinine (Crn) tests were perfonned pre and post intervention. 
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I .2 Research Questions 
I. Will there be an increase in total muscle mass ofP.lderly males as a result of taking 
creatine monohydrate? 
2. Will supplementation with creatine monohydrate support extra training in elderly 
males corn pared to a training and placebo condition? 
3. Will there be a difference in isometric and isokinetic force production and 
endurance as a result of supplementation with creatine monohydrate in elderly 
male-s? 
4. Will there be a difference in trained versus non-trained limbs with creatine 
monohydrate supplementation? 
1.3 Research Hypotheses 
l. Muscle mass will increase significantly in the creatine group but not the placebo 
group. 
2. ft.11Jscle strength will increase significantly more in the creatine group than the 
placebo group. 
3. Muscular endurance will increase significantly more in the creatine group than the 
placebo group. 
4. Muscle mass will increase more in the trained leg than the untrained limb following 
training in the placebo group. 
5. Muscular strength will increase significantly more m the trt'ined leg than the 
untrained limb following training in the placebo group. 
6. Muscular endurance will increase more in the trained leg than the untrained limb 
following training in the placebo group. 
7. Muscle mass wilt increase significantly more in the trained leg than the untrained 
limb following training in the creatine group. 
8. Muscular strength will increase significantly more in the trained leg than the 
untrained limb following training in the creatine group. 
9. Muscular endurance will increase more in the trained leg than the untrained limb 
following training in the creatine group. 
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CHAPTER TWO 
Literature Review 
2.1 Sarcopoenia 
Sarcopoenia is described by Hurley & Roth (2000) as a loss of strength with advanced 
age and is associated with a deterioration of health status. Muscle mass and cross· 
.• 
sectional area reaches a peak at approximately 30 years of age and then a steady decline 
occurs during the fortieth decade, accelerating to around 12 to 14% per decade after the 
age of 50 years (Roth et at., 2000). Between the ages of30 and 80 years ovemll muscle 
strength and mass may decline by 30-50% (Frischknecht, 1998; Roth et al., 2000). After 
70 years of age a further increase in the rate of strength and mass loss is evident, as 
much as 30% of strength may be lost between the ages of70 and 80 years (Frischknecht, 
1998). Losses in muscle mass and strength with ageing are similar to those resulting 
from inactivity (Hurley & Roth, 2000). The decrease in muscle strength is closely 
correlated with changes in muscle cross-sectional area, suggesting that much of the 
strength loss in ageing is explained by loss of muscle mass rather than neurological 
factors (Frischknecht, 1998). Studies which have examined muscle biopsy samples 
from older subjects have described a greater decrease in cross-sectional area of whole 
skeletal muscles than that of individual muscle fibres (eg. Grimby & Saltin, 1983). 
This has led to the conclusion that the reduction in muscle fibre size cannot fully 
explain the loss in muscle mass, but that a reduction in fibre number must also occur. 
Furthennore, there appears to be a difference in the rate of atrophy between muscle 
fibre types. The available evidence for changes in muscle fibre type with age is 
conflicting, with some studies showing that Type I fibres area is unchanged up to the 
age of about 80 years, but Type ll fibres show significant atrophy, with a reduction of 
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around 26% for quadriceps femoris by the age of SO years (Larsson et al., 1978). Other 
investigations have found an increased proportion of Type I fibres in 65 year olds 
compared with 25 year old subjects (Lexell, 1993). According to Roos et al., (1996) 
there is no conflict regarding the evidence for a reduction in cross-sectional areas of 
individual muscle fibres with advancing age. At the age of approximately forty years 
Type II fibres are around 20% la'l!er than Type I fibres, but Type II fibres measure 
about 50% for cross-sectional of Type I fibres by the age of85 years {Roes et al., 1996). 
In a 12 years longitudinal study, Frontera et al., (2000) recorded a 20-30% loss in 
isokinetic stren,gth of elbow and knee flexors and extensors for individuals who were 
about 65 years of age at the first test session. Cross sectional area of the thigh muscles 
were reduced by approximately 15% after 12 years. They also reported a rate of strength 
loss of2.5% per year for knee flexors and 2.0% per year for knee extensors. The authors 
showed a loss of muscular strength with age in their subjects at both fast and slow 
angular velocities for knee extensors and flexors as well as elbow. The same study 
reported showed a significant decrease in cross sectional area of muscles and a decrease 
in Type I to Type II fibre ratio, leading the authors to conclude that a quantitative loss in 
muscle mass is directly linked to the associated loss of strength in elderly males. They 
went on to recommend that increased physical activity in sedentary, healthy older males 
may reduce the effects of disability due to this gradual loss of strength. 
Kent-Braun & Ng (2000) studied the effects of ageing on the oxidative capacity of 
skeletal muscles in young and older males and females. They found that skeletal 
locomotor muscles of healthy older males and females showed no deficit !n oxidative 
capacity compared to the muscles of younger men and women of similar physical 
activity levels. This suggests that loss in oxidative capacity is not a direct :;onsequence 
of ageing. This investigation also found that PCr recovery was not different between the 
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groups and that there was a wide range ; 1 PCr recovery values between the older and 
younger participants (Kent-Braun & Ng, 2000). They concluded that most of the 
variation in oxidative capacity between individuals could be accounted for by 
differences in physical activity levels, and was not related to the effects of ageing per se. 
2.2 Stren!;th Training and the Elderly 
Strength training increases muscular strength and cross-sectional area in young adults 
(Frischknecht, 1998). Mass increases are due to greater cross-sectional area of both 
Type I and Type II fibres and possibly a greater number of individual fibres. There is 
some controversy regarding the possibility of increasing fibre number (hyperplasia) in 
response to training (Frischknecht, 1998). However, even in those subjects described as 
very old (more than 80 years of age) studies have shown that skeletal muscle strength 
and mass can be improved with resistance training. For example, Fiatarone et al., (1990) 
looked at male and female nursing home residents who were instructed on how to 
perfonn a series of exercises designed to strengthen their knee extensor muscles. These 
included 3 sets of 8 eccentric and concentric repetitions performed 3 times weekly for 8 
weeks at a training load of80% of their one repetition maximum (RM). The resistance 
was increased progressively every two weeks. Over the course of training, quadriceps 
muscle strength increased by an average of 174% and cross-sectional area was 11% 
greater. These changes were accompanied by a mean improvement in walking speed of 
48%. Interestingly, despite these dramatic gains in muscle area and function, all indices 
had declined to pre-investigation levels 4 weeks after participants returned to their 
normal routine. 
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2.3 Creatine 
Creatine is a nonessential dietary element, found in meat and fish (Terjung et al., 2000). 
Produced endogenously in the body it is an energy-producing substance that is 
synthesized in the liver, pancreas and kidney from amino acids (Harris et al., 1992). 
Creatine is also ingested from animal products (Kreider~ 1998). Creatine synthesis is a 
two step reaction, firstly guanidinoacetate is formed from arginine and glycine in a 
reaction catalyzed by arginine:glycine amidinotransferase. In the second step s-
adenosylmethionine, a methyl group is transferred to guanidinoacetate fanning creatine 
(Teljung et al., 2000). Some of the creatine is phosphorylated to form creatine 
phosphate, also called phosphocreatine (PCr). PCr has four main functions in skeletal 
muscle metabolism. It allows for the rapid rephosph01ylation of ADP during periods of 
transition between rest and exercise as well as during short periods of high intensity 
exercise. Secondly, it enhances the capacity for high energy phosphate diffusion from 
mitochondria to myofibrils. PCr also serves as a buffer against the development of 
intracellular acidosis during exercise. Lastly, Cr and inorganic phosphate, the products 
of PCr hydrolysis, are important for activation of glycogenolysis and other catabolic 
pathways (Tetjung et a!., 2000). There are many occasions during exercise when 
mitochondrial ATP production via oxidative phosphorylation is insufficient to support 
the energy metabolism required for the maintenance of work output. These include 
situations of high intensity exercise, the rapid transition from one exercise level to a 
higher intensity, and occasions where oxygen availability is reduced. In such situations 
energy is provided via PCr phosphorylation and glycogenolysis/glycolysis (Tetiung et 
at., 2000). 
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Ninety five percent of creatine is found in muscle tissue, its concentration nonnally 
being in the range ofiOO to 140 mmol/kg dry mass (DM) (Mathews & Van Holde, 1996, 
p266). Creatine is broken down to creatinine (Cm) in skeletal muscle after which it 
diffuses into the bloodstream before being excreted in the urine (Valek, 1999a; Benzi, 
2000). For this reason, one way of measuring creatine intake and metabolism is the use 
of urinary Cm collections (made over a 24 hour period). In the absence of Cr 
supplementation, muscle Cr stores are metabolised at a constant rate of approximately 2 
grams per day (Valek, 1999a). Muscle creatine stores must be replenished from dietary 
sources or by endogenous synthesis to maintain sufficient intramuscular Cr and PCr 
levels for optimum physiological function (Feldman, 1999). If dietary Cr exceeds that 
required to maintain muscle stores, it is converted to Cm and readily excreted by the 
kidneys, there being no renal threshold for the urinary excretion ofCm (Feldman, 1999). 
Studies which have investigated Cr uptake in subjects ingesting supplementary CrH20 
using urinary Cm as a measure have found that the greatest muscle Cr uptake usually 
occurs within the first 2 days of supplementation (Odland et a!., 1997). This method, 
however, is a very imprecise measurement, as endogenous Cm excretion varies among 
individuals due to physical activity, maturity, metabolic state and gender (Lukaski, 
1997). 
Energy for muscle contraction is obtained when adenosine triphosphate (ATP) is 
stripped of a phosphate to form adenosine diphosphate (ADP), with the released 
chemical free ener!,')' converted into mechanical work. For short-term anaerobic 
exercise, the high-energy phosphate is donated by PCr to replenish ATP stores. Skeletal 
muscle contains approximately 80 to 100 grams of ATP, which is only enough to 
support performance of high intensity exercise for several seconds (McArdle, Katch & 
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Katch, 1996, p102). Creatine has a high phosphate transfer potential and so this 
compound is capable of phosphorylating ADP very efficiently as shown in figure I. 
(Mathews & Van Holde, 1996, p266). 
Creatine Kinase 
Creatine Phosphate + ADP +------.Creatine + ATP 
Figure I. The energy source in muscle is creatine phosphate, which regenerates ATP 
continually as it is depleted by muscle contraction. 
As the equilibrium constant lies to the right of this reaction, almost all muscle adenyl ate 
is maintained in the form of ATP while creatine phosphate is available. Creatine 
phosphate always tends to transfer its phosphate to adenosine diphosphate in order to 
replenish the ATP (Mathews & van Holde, 1996 p266). This reaction can generate 
enough power for 4 seconds of muscle contraction (Feldman, 1999). During recovery 
after strenuous exercise, the CK reaction is reversed to produce PCr and ADP. 
2,3. I Creatine Kinase (CK) 
Creatine kinase is an enzyme that catalyses biochemical reactions that occur 
intramuscularly. CK's primary role is to convert a phosphate group to Cr, resulting in a 
high-energy molecule PCr. Plasma CK levels are also used in many research and 
clinical studies as it is an indicator of skeletal muscle damage (Schwane et al., 2000). 
When the muscle is damaged due to injury or exercise, muscle cells break down and, as 
CK is normalty found in muscle, a rise in the levels of plasma CK indicates that muscle 
damage has occurred (Schwane et al, 2000). 
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2.4 Creatine Supplementation in Athletes 
PCr depletion is a limiting factor when perfonning exercise (Rossiter et al., 1996). The 
first study into the use of Cr supplementation in humans for the purpose of improving 
perfonnance was conducted by Harris et al., (1992). They used a diverse group of 
subjects (five females and 12 males between 20 and 62 years) who varied greatly in 
their fitness levels. There was no training protocol in place for most of the subjects, but 
five of the subjects conducted a one leg bicycle ergometry training regimen for one hour 
each day during the experimental period which lasted not more than seven days. On 
average there was a significant increase in the total creatine pool, although no increase 
in muscle ATP content occun·ed. This study showed that exercise can increase the 
amount of Cr taken up with supplementation in individual muscle groups. The training 
leg of the subjects, who took part in the single leg training programme, had an increase 
in total Cr in the trained muscle of27.2% compared to 20.5% in the untrained leg using 
muscle biopsy samples. The authors suggested that supplementation with Cr could have 
a benefit in athletic perfonnance because Cr uptake is enhanced when taken in 
conjunction with regular exercise. This could be best explained by an increase of blood 
flow to the working muscles, although it is also possible that a change in the transport 
kinetics of Cr across the fibre membranes may have contributed to the observed 
findings (Harris et al., 1992). 
Many studies have since been carried out to detennine the effect of Cr supplementation 
on skeletal muscle strength and mass in young healthy recreational athletes (Balsam et 
al., 1993; Earnest eta!., 1995; Casey et al., 1996; Prevost et al., 1997; Valek et al., 
1999; Becque et al., 2000; Edwards et al., 2000). In the study by Valek et al., (1999) 
CrH20 supplementation proved to be beneficial for high volumes of heavy resistance 
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training in ten, already well trained individuals. The creatine group saw much faster 
improvements in strength than the placebo group. These findings were explained on the 
basis that the increased intracellular PCr resulting from supplementation allowed for 
ATP replenishment to take place at a faster rate, which, in tum, allowed athletes to train 
at a higher intensity during individual sessions. 
During maximal exercise PCr acts as a buffer maintaining the ATP/ADP ratio within 
the muscle by donating its phosphate as the ATP is depleted (Rossiter et al., 1995). 
Valek et al., {1999) concluded that the increases in fat free mass observed following 
CrH20 supplementation are a consequence of skeletal muscle fibre hypertrophy because 
the subjects were able to maintain a higher training volume than the placebo group for 
the reasons explained previously. Other researchers have reported similar findings. 
Rossiter et al., (1995) found a non-significant increase in rowing performance of trained 
rowers who took CrHzO for five days. These participants improved their maximal 
rowing time by 2.3 seconds over the five days compared to a placebo group who 
experi,~nced no change in performance. A number of studies have shown that during 
intermittent exercise bouts CrH20 supplementation can support extra work. In a study 
using ten bouts of 6 seconds maximal effort cycling with rest periods 'Jf 30 seconds it 
has been shown that the group supplemented with CrH20 had a smaller decline in work 
output from baseline to the final bout (Balsom et al., !993). Prevost et al., (1997) 
showed an increase in time to exhaustion and total work time with CrH20 
supplementation in physically active physical education students compared to a placebo 
group in repeated bouts of maximal voluntary cycling. The four types of bouts were 
continuous cycling to exhaustion, thirty seconds of cycling with sixty seconds rest, 
twenty o;;econds of cycling with rest periods of forty seconds and ten seconds of cycling 
separated by twenty seconds rest. This study found CrH20 supplementation 
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significantly increased time to exhaustion and total work time in every one of the four 
protocols tested (Prevost et al., 1997). 
The increase in body mass and fat free mass (FFM) associated with CrH20 
supplementation is well documented (Salsom et al., 1993; Earnest et al., 1995; Casey et 
al., 1996; Prevost et al., 1997; Volek et al., 1999; Becque et al., 2000; Edwards, et al., 
2000; Chrusch et al., 2000). The effects have been attributed to increases in total body 
water (TBW), increased muscle fibre size and enhanced protein synthesis. Haussinger 
and colleagues (1993) posit that, since Cr is an osmotically active substance, increasing 
intracellular Cr levels will lead to greater intracellular hydration, leading to myofibre 
swelling. This belief is further supported by reports of lowered urinary output and an 
increase in body mass during CrH20 supplementation as a result of water retention 
(Hultman et al., 1996). In addition, Preen and colleagues (2001) found evidence to 
suggest that CrH20 supplementation was associated with increased protein synthesis, 
which may aiso contribute to the elevations in body mass observed with Cruse. Other 
authors reported that the increased body mass associated with CrH20 supplementation 
was associated with increased muscle DM in the absence of any changes in body fluid 
levels, thus arguing against a role of fluid retention in the changes in body mass 
observed (Francaux et al., 2000). 
Francaux and Poortmans (1999) using bio·impedance spectroscopy to measure body 
water content, showed that 55% of the body mass increase after nine weeks CrH20 
supplementation occurred due to an increase in intramuscular water content. 
Importantly, Cr ingestion for longer than several weeks in healthy subjects results in a 
much greater improvement in both strength and lean muscle mass than shorter term 
studies (Volek et al., 1997; Prevost et al., 1997; Francaux & Poortmans, 1999; Volek et 
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al, 1999a). Most of the studies investigating the effects ofCrH20 supplementation have 
used high intensity resistance training programs. In contrast, Kamber et al., (1999) used 
cycle ergometry exercise as a training intervention in conjunction with CrH20 
supplementation and high intensity sprint repetitions as a test of functional perfonnance. 
They found that the CrH20 supplemented group had a significant improvement in 
perfonnance over the last three sprints, and lower levels of blood lactate in a series of 
ten sprint repetitions. The authors concluded that Cr supplementation not only 
improved the capacity for heavy resistance training, but also high intensity ergometer 
based exercise. 
2.5 Creatine Supplementation in Non~athletes. 
Although a decrease in muscle mass is associated with aging (Welle et al., 1996), it is 
likely that other factors contribute, including a lack of physical activity, degenerative 
disorders, and poor nutrition (Fiatarone et al., 1990). Resistance training is considered a 
viable inteiVention for reversing the reduction in muscle function and degradation of 
structure in the elderly. Hurley and Roth (2000) suggested that resistance training in the 
elderly should focus upon an improvement of life quality by preventing disability and 
progression of disease through modification of risk factors as well as improving 
cardiovascular and metabolic function. These can help to improve muscle mass, 
strength, power, flexibility and bone mineral density (BMD) (Hurley and Roth, 2000). 
While there have been many studies into the use of creatine supplementation in athletes, 
research into the possible benefits for non-athletes is less common. Some research has 
been undertaken in the areas of supplementation for young sedentary people (Harris, 
Soderlund & Hultman, 1992), older populations (Bennon et al., 1998; Rawson et al., 
1998; Chrusch et al., 2001) and in various pathological groups (Walteret al., 1999). 
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Walter et al., (1999) used Cr supplementation in patients with vanous fonns of 
muscular dystrophy. This study employed a double blind, piacebo-controlled, crossover 
design with a 3~week washout period. The subjects were evaluated for strength using 
manual assessment (MRC scale) and the patients own assessment of any changes. The 
researchers found a significant improvement in all evaluations and the patients1 own 
assessment in the CrH20 compared to the placebo group. There were no side effects 
reported during this study. Some studies have reported anecdotal evidence of nausea, 
vomiting and diarrhoea as welt as an increased incidence of muscle cramps and strains. 
There have also been reports of hypertension in athletes supplementing with Cr 
(Teljung et al., 2000). A recent study by Stout and colleagues (2001), has demonstrated 
that CrH20 supplementation during resistance training in a patient with myasthenia 
gravis resulted in increases in FFM, muscular strength and training volume. In contrast. 
patients receiving a placebo substance showed significantly smaller improvements when 
given the same training regimen. 
It has been suggested that a low muscle PCr concentration may contribute to fatigue in 
activities of daily living where high-energy demands are placed on the muscles and that 
intramuscular PCr may be increased by CrH20 supplementation (Tamopolsky and 
Praise, 1999). There is evidence that short tenn CrH20 supplementation can increase 
intramuscular PCr and total creatine concentrations by as much as 15 to 20 percent in 
nonnal subjects (Harris et al., 1992; Vandenberghe et al., 1997) and also in patients 
with cardiomyopathies (Gordon et al., 1995). Interestingly, individuals with the lowest 
concentrations of muscle PCr showed the greatest increase in response to 
supplementation (Gordon et al., 1995). 
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Tamopolsky and Praise (1999) measured high-energy phosphate compounds in patients 
with neuromuscular disease and found PCr concentrations were significantly lower in 
patients with inflammatory myopathies and muscular dystrophy in comparison to 
normal controls. On differentiating patients by disorder groups as mitochondrial 
cytopathy, neuropathy, inflammatory myopathy, dystrophy/congenital myopathy or 
miscellaneous, they found that the PCr levels for patients with inflammatory 
myopathies and muscular dystrophy were significantly lower than the normal subjects 
and suggested that they may stand to benefit from creatine supplementation. A follow 
up study was conducted in subjects with the same neuromuscular disorders, which 
looked at body weight and strength measures including hand grip strength, ankle 
dorsiflexion strength and dorsiflexion fatigue. The authors found a significant 
improvement in all tests following CrH20 supplementation of lOg for five days and Sg 
for five days (Tarnopolsky & Martin, 1999). A further study into creatine transporter 
and mitochondrial creatine kinase protein content in myopathies concluded that creatine 
transporter protein is lower in some neuromuscular disorders, which also have lower 
phosphocreatine concentrations and total creatine. The authors suggest supplementation 
with CrH20 may help reduce the rate of muscle degradation in these patients. They 
further recommend long term, randomised, double-blind studies of CrH20 and 
intracellular high-energy phosphates and how these may impact on strength reduction in 
these groups (Tamopolsky et al., 200 I). 
fu what is probably the most comprehensive study of the effects of CrH20 
supplementation and training in a non-athletic population to date, Bennon et aJ., (1998) 
placed a group of elderly, sedentary people into four test groups; creatine and training, 
creatine only, placebo and training and placebo only. The control groups did not 
participate in any resistance training. The exercise intervention consisted of chest press, 
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leg press and leg extension. They found that both of the training groups had significant 
increases in one repetition maximum scores as follows: control grotlp, chest press 
(+7.8%) and leg extension (+5.7%), training group, chest press (14 7%), leg press 
(+14.0%) and leg extension (+18.1%). The changes in 12 repetition maximums for the 
control group were chest press (+6.7%) and leg cxfcnsion (+6.0%)_ The training group 
increased their pre-test scores for leg press, chest press and leg extension by 17 5%, 
16.2% and 17.1% respectively. Comparing training in combination w·ith CrlhO 
supplementation, the control placebo group showed no significant increase~ for one 
repetition maximum. The training placebo group showed an incre11 n lc~ press 
(+J(J 1• 0-~). chest press (+11.7%) and leg extension (+17.0%) and the training creatine 
group showed significant increases for leg press (+ 17.3), chest press ( + 17 .4~0) and leg 
extension (+18.9). A five day urine analysis was conducted six months after the 
experimental period in which the subjects ingested 20 grams of CrH 20 daily fur five 
days. This showed that creatine loading was probably not fully achieved as the 
coefficients of variation for creatine and creatinine were 1 and 2 5% respectively 
(Bennon et al., 1998). The authors concluded that CrH20 supplementation did not 
improve strength and muscle mass but that exercise was the major contributing factor 
They speculated that elderly subjects may need a longer period of loading to bring the 
muscle Cr concentration to a level that can sufficiently support extra training Jnd this is 
why there was no significant difference between the Cr and placebo groups. 
Chrusch et al., (2001) used a double-blind, placebo controlled design with 12 weeks 
CrH20 supplementation in which the dosages used were similar to that recommended 
for athletes (0.3 g!kg body weight for the loading phase and 0 07 g!kg body weight for 
the maintenance phase). The elderly male subjects \Vcrc separated into c!c<J.tinc (mean 
age = 70.4 years) and placebo groups (mean age = 71.1 years) and strength v.·as assessed 
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by one repetition maximum lifts for leg press, knee extension and bench press. The 
same exercises were employed to test muscular endurance, but in this case the 
maximum number of repetitions for three sets at an intensity equivalent to 70%-80% 
baseline one repetition maximum for bench press, knee extension and leg press. The 
training protocol consisted of an individualised, supervised gym-based, whole body, 
programme. The authors found that the c~~atine group were able to train harder than the 
placebo group, and completed a trai'ling volume which was 30% greater over the course 
of the programme. Creatine ingestion and training resulted in an increase in lean body 
mass of 5.7% (average = 3.3 kg) compared to 2.5% (average = 1.3 kg) for the PLA 
group. They also experienced a greater increase in muscular strength for all lower body 
exercises. The researchers concluded that creatine had a positive effect on m1.:s.~ular 
petfonnance, especially for the lower limbs, in older males who were inexperienced in 
resistance training. The apparent contradiction between the findings of the Bennon et 
al., (1998) study and the Chrusch et al., (2001) investigation may be related to the 
dosages of supplementation used. Bennon et al., (1998) used a loading dose of20 g per 
day for five days and 3 g per day for the remaining 42 days and Chrusch et al (2001} 
used a grams of CrHzOikilograms body weight dosing protocol giving the average 
loading dose of 26.4 g per day for five days and a maintenance dose of 6.2 g daily, thus 
using a maintenance dose over twice that of the earlier study. Whereas, Bennon eta!., 
(1998) found no significant change in body mass in any of the four groups during the 
study, Chrusch et at., (2001) showed an increase of 5.7% lean body mass for the 
creatine group compared with a 2.5% increase for the placebo group. 
Short-term (5 - 7 days) Cr supplementation studies have been shown to increase both 
lean body mass and intramuscular PCr stores (Balsam et al., 1993; Kreider, 1998a). 
Kreider (i 998a) reported a 0.6 - 1.1 kg increase in body mass, but as described 
19 
previously, most of the increases in body mass resulting from CrHzO supplementation 
have been attributed to increased total body water content rather than an increase in 
myofibrillar protein synthesis. 
Long-term (> 4weeks) Cr supplementation studies on healthy individuals, show greater 
gains in strength and lean body mass (Kreider, 1998b) than studies involving 
supplementation over several weeks only (Vdek et al., 1997). Long-tenn 
supplementation ofCr (a typical supplementation regimen consisting of25 g daily for 5 
- 7 days and 2 - 5 g daily for up to 12 weeks) promotes significant gains in strength, 
body mass and FFM in conjunction with a training program in comparison to placebo 
controls (Kreider, 1998a). Pepping (1999) suggests that these improvements are mainly 
due to the uptake of amino acids into contractile muscle proteins thus stimulating 
protein synthesis. However, not all studies have found improvements in performance to 
be an outcome ofCrH20 supplementation (eg. Stevenson & Dudley, 2001}. 
One of the problems encountered when attempttng to compare the results of different 
studies which have used CrH20 supplementation is the wide range of dosages used. 
This is due, at least in part, to the lack of consensus as to optimal dosage and duration, 
as well as issues relating to the efficacy and safety of different supplementation 
protocols. Although a loading phase of 20 g daily has been used in many research 
studies as it seems to be optimal for producing the most rapid increases in muscle Cr 
concentrations (Schilling et al., 2001}, the same muscle PCr concentrations can be 
achieved with lower doses ofCr (3 g daily) but extending the loading period (Teljung et 
at., 2000). It has been suggested that the lower supplement dose can reduce the potential 
of developing side effects (Schilling et al., 2001). Volek and colleagues (1999b) have 
shown that as little as 2 g of Cr ingested daily can improve intramuscular Cr levels in 
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men who are not exercising vigorously, whilst Harris and associates (1992) found that 
four to six doses of 5 g of Cr for 2 days produced a significant increase in TCr stores in 
the quadriceps femoris muscle of 17 subjects. It is interesting to note that Harris et at., 
(1992) found that the greatest improvements in muscle Cr concentration were seen in 
subjects with an initially low Cr content. 
The washout period for intramuscular Cr (ie. the time taken for muscle Cr to return to 
pre~supplementation values) can be quite variable. Following Cr supplementation, 
muscle Cr concentration can remain elevated for weeks or even months depending on 
the initial dosage ingested (Maughan, 1995). Feldman (1999) and Wyss & Kaddurah -
Daouk (2000) reported that muscle Cr and PCr concentrations returned to baseline 
levels approximately 30 days after cessation of short tenn CrH20 supplementation. 
Vandenberghe and coworkers (1997) found that muscle PCr and urinary Cr and Cm 
excretion returned to normal values after four weeks of long~term Cr supplementation 
was stopped. 
There are conflicting reports as to the effectiveness of CrH20 supplementation in 
improving performance (Stevenson and Dudley, 2001; Yquel et al., 2002). Cr 
supplementation has been reported to have a reduced ergogenic effect when the 
supplementation regimens are short tenn and involve less than 20 grams per day or with 
regimens that do not have an initial loading phase (Kreider, 1998a). Stevenson and 
Dudley (20011 in a double-blinded placebo experiment on a group of resistance trained 
subjects, found that Cr supplementation did not increase the level of PCr usage or rates 
of recovery during maximal voluntary or electrically stimulated muscle strength and 
endurance tests. They concluded that Cr loading did not provide an ergogenic effect for 
knee extensions exercises and suggested that CrH20 supplementation may even slow 
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PCr replenishment. These negative findings may be due to the supplementation protocol 
used, with a CrH20 loading phase of only one week and the absence of a maintenance 
phase of supplementation. 
The failure to find a consistent positive effect of CrH20 supplementation on 
perfonnance may be due to a variety of factors, including sub-optimal dietary 
absorption of, or intracellular uptake of, Cr by subjects (Valek, 1999a). Other factors 
which have been cited in contributing to the apparent conflict in the findings of studies 
in this area include general methodological issues such as familiarisation of the subject 
with the equipment prior to testing, time of the day when testing occurs, number of 
subjects involved, drug and nutrient intake, length of supplementation and the type of 
activity programme (Kreider, 1998a; Tamopolsky & MacLennan, 2000). 
2,6 Possible Side Effects 
There have been some reports that prolonged or excessive Cr ingestion can result in 
deleterious effects such as muscle cramping, nausea, gastrointestinal discomfort and 
skin rash (Rawson, Wenhert & Clarkson, 1999; Valek, 1999). However, most studies 
have found that subjects are able to tolerate standard supplementation with few 
problems. (Walter et al., 1999; Tamopolsky & Praise, 1999). It is possible that the 
reports of side effects associated with CrH20 supplementation may be related to 
excessive doses over long periods. eg. Koshy, Griswald and Schneeberger (1999) 
reported a case study of a previously healthy 20-year-old male who presented with 
nausea, vomiting and bilateral flank pain. This man took 5 g ofCrH20 four times daily 
for four weeks. This caused problems with his renal function and he returned to normal 
after ceasing supplementation. Chrusch et al., (200 1) reported side effects significantly 
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more frequently in the Cr than the placebo group. Problems reported included loose 
stools during the loading phase and increased muscle cramping and muscle strain after 3 
and 5 weeks of supplementation. 
2.7 Summary 
Since the original investigations of Harris et at., (1992) many researchers have since 
conducted studies of the effects of CrH10 supplementation, although the results have 
not always been consistent. The majority of investigations have used young, healthy, 
and often athletically trained, participants (Balsam et al., 1993; Earnest et al., 1995; 
Casey et al., 1996; Prevost et al., 1997; Valek et al., 1999), others elderly (Berman et al., 
1998; Clarkson & Melanson, 1999; Chrusch et al., 2001). A few studies have involved 
elderly subjects and individuals with neuromuscular disorders (Walter et al.. 1999; 
Tamopolsky & Praise, 1999; Tamopolsky & Martin, 1999; Tamopolsky et al., 2000). 
The rationale for the present study is that an improvement in muscle function with 
CrH20 supplementation and/or home-based low-intensity resistance training in older 
subjects would have the potential for use in improving the quality of life and reducing 
morbidity in this population. 
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CHAPTER THREE 
Materials and Methods 
3. I Subje~ts 
Ethical approval was granted through the Edith Cowan University Ethics Committee for 
the conduct of this project prior to the study. Subjects participating in this study 
provided written informed consent (Appendix A), completed a health check 
questionnaire (Appendix B) and were evaluated by a medical practitioner in order to 
screen for any contra-indications for participation in the study. 
Participants consisted of healthy ... relatively sedentary males aged between 61 and 75 
years. Volunteers were recruited via advertisement in the local Community Newspaper 
and notice boards at the local campus of the University. Twenty-five men volunteered 
for this study. Volunteers passed as being medically suitable for participation were 
given further information regarding the study methodology and arranged for laboratory 
visit for orientation. 
Seventeen participants started the study, of these, eleven completed the entire protocol. 
Table I. Physical characteristics of subjects prior to commencement of the 
supplementation and training programme 
Group 
Creatine 
mPlacebo 
Number 
8 
9 
Age (Mean±SD) 
68.25 ± 3.31 
64,33 + 3 40 
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Height (em) Weight (kl:l) 
171.2 82.5 
173.9 80,0_ 
Subject attrition occurred for a number of reasons. none of which were related to the 
study itself. These included illness, personal problems, relocation and work 
commitment~ any of which were reasons given by for withdrawal from the study. 
As discussed in the previous chapter it has been suggested that previous researchers 
have not allowed sufficient time for Cr loading to occur in older subjects (Rawson et al, 
1999). In nonnal, young, active adults, 5-10 days at 20-25 g of CrH,O per day is 
regarded as sufficient to increase total intramuscular PCr levels to a point where 
positive ergogenic effects are seen. Since, in older individuals, the conversion of the 
extra Cr to Cm seems to occur more readily than in younger people, it was decided to 
use a loading phase ofl4 days at IS g ofCrH,O daily. 
3.2 Pesi!!D 
3,2,1 Equipment 
Powdered creatine monohydrate (6kg) (Aussie Bodies) 
Powdered dextrose (6kg) (Aussie Bodies) 
Electronic chemical balance (to weigh out creatine and dextrose) (Mettler PM 4600 
Deltarange) 
Rubber gloves 
Gelatin capsules (each holds I gram Cr or dextrose){Surgi Pack size "000") 
Cybex 6000 isokinetic dynamometer (Ronkonkoma, NY, USA) 
DEXA scanner (Hologic QDR 4500) (Bedford, MA, USA) 
Reflotron Spectrophotometer (Boehringer-Mannheim - Pode, Czech Republic) 
Creatinine assay strips (Boehringer·Mannheim- Pode, Czech Republic) 
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Capillary tubes and pipette (Boehringer-Mannheim - Pode, Czech Republic) 
Ankle Cuffs ( 16x5kg; 4x I Okg) (Australian Barbell Company) 
Weight poles (40x500g & 4x250g) (Australian Barbell Company) 
Electronic scales (0-120kg) (for body weights) (Mettler IDI Multirange) 
Stationary cycle ergometer (for subjects to use as warm up for Cybex tests) (Repco) 
Training diaries (see Appendix C) 
3.2.2 Supplementation 
The supplementation occurred in a double~blind fashion. In order to ensure that neither 
the subjects nor the experimenter knew to which group each subject belonged, the 
creatine and dextrose were placed in capsules containing I g of each agent. The 
capsules were filled manually on a clean bench top and bench cover. Rubber gloves 
and dust masks were used at all times to ensure the working area remained 
uncontaminated. An independent party allocated the subjects to either the creatine (8) 
or placebo (9) group. The creatine group took 15 g of CrH,O in 3 x 3 g doses per day 
during the loading phase (14 days) and 3 g per day in the maintenance phase (10 weeks). 
The placebo group consumed an equivalent amount of dextrose, in identical capsule 
forms. The capsules were used to prevent the possibility that subjects might identifY 
CrH20 from its characteristic taste. 
3,2.3 Training Protocol 
All subjects followed the same training protocol. Training was carried out on the knee 
extensors and flexors with an adjustable ankle cuff and weights were set and reviewed 
at each test session. The subjects were instructed to increase the number of sets to 3 per 
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session when the training felt too easy and then begin increasing the weight for a further 
training stimulus. Only one randomly selected leg was trained. The training regimen 
consisted of leg flexion in a standing position and leg extension in a seated position as 
shown in figures 2 and 3. The first training weight was 3 kg (or approx 30% of 
isometric maximum voluntary contraction torque) and each subject adjusted the weight 
to suit. Training started with one set of 12 repetitions of each exercise daily and the 
weight and sets were increased according to the instructions above, as the training 
became easier an increment of 250 or 500 g was made. Each training session lasted no 
more than five minutes. In case, during the first weeks, the subjects experienced some 
muscle soreness they were instructed to take a day off training if they considered this 
too severe, however supplementation was to remain constant. Each subject was given a 
simple training diary to fill in (Appendix C), which was used to quantify the volume of 
training as a product of reps and weight. Subjects were asked to bring their training 
diaries to the testing sessions to ensure they were continuing the program as instructed 
and their training progress was discussed in case they had any problems or questions. 
Subjects were contacted on a weekJy basis to monitor progress or deal with any 
questions or issues they may have had. 
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a) b) 
Figure 2a & b. Leg flexor training. 
a) b) 
Figure 3a & b. Leg extensor training. 
28 
3 .2.4 Testing 
Testing sessions were canied out at times most convenient to the volunteers and was 
subject to the availability of the testing equipment. Although all tests were conducted in 
the same laboratory, there was no standardization of room temperature or any other 
environmental condition or time of day. 
3.2.4.1 Body Composition 
Dual-energy X-ray absorptiometry (DEXA) was used to quantify bone and soft tissue 
mass and composition. The technique differentiates body tissue into three 
compartments based on tissue density, lean soft tissue, fat soft tissue and bone. DEXA 
has proven to be a reliable method of quantifying body composition for regional as well 
as whole body parameters (Pollock et al., 1995). Body composition scans were carried 
out at the Bone Density Unit at Sir Charles Gairdner with data obtained for total body 
mass and differentiated whole body fat and lean body mass. Scans were also taken of 
the left and right upper legs to quantifY the mass of the limb segment. Limb segments 
were manually cursored from the scans based on anatomical landmarks of knee joint 
and greater trochanter. DEXA scans were perfonned on each subject prior to 
supplementation and after the 12 weeks training/supplementation programme. An 
example of the DEXA scan data is included in Appendix D. 
3.2.4.2 Isometric and Isokinetic Strength and Endurance 
Muscle function assessment was carried out using a Cybex 6000 lsokinetic 
Dynamometer (Ronkonkoma, NY, USA). Subjects warmed up at a self-selected pace 
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on a Repco stationary cycle for 5 minutes before being securely restrained in an upright 
seated position on the dynamometer (Figure 4). Hip alignment was adjusted so that the 
line from the hip to the knee was perpendicular to the rotating ann of the dynamometer, 
and the axis of rotation of the ann was level with the lateral epicondyl:: of the tibia. The 
dynamometer arm was adjusted so that the pad could be attached as low on the shin as 
possible without touching the foot. An additional strap was used to prevent the knee 
from lifting off the seat during each extension. The test sessions lasted not more than 
one hour and included isometric strength of knee flexors and extensors at three different 
angles (45, 60 and 75 degrees) and each angle was tested three times before moving to 
the next one. The subject had 20 s to produce a peak force contraction of the extensors 
and the flexors and as this was more than enough time there was no programmed rest 
period. lsokinetic tests at three different speeds (60, 180 and 240 degrees per second) 
were carried out next. The subject was asked to extend and flex the leg at the knee 
through a preset range of motion (approx 80°) as quickly as he cculd for 4 repetitions 
and given 30 seconds rest between each set. The testing session for each leg concluded 
with an endurance task consisting of 5 sets of 15 repetitions at 180 degrees per second 
with 30 s interval between sets. After this was completed the subject was released from 
the dynamometer and given the opportunity to walk around the laboratory, stretch and 
drink some water while the investigator adjusted the dynamometer for the other leg. The 
test protocol was then repeated for the contralateral limb, with the order of testing 
randomised between left and right limbs. All tests required maximal effort. In order to 
minimise the likelihood of subjects perfonning sub maximally during the testing, they 
were given strong and consistent verbal encouragement throughout. Subjects were also 
provided with visual feedback of their torque output for each contraction in order to 
give them a target torque to reach each time (Fig 4). Testing took place prior to 
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beginning the training and supplementation and repeat testing occurred at the end of 
weeks 2, 7 and 12 of the study. 
" Figure 4. Strength testing using the Cybex 6000 Isokinetic Dynamometer 
3.2.4.3 Plasma Creatinine (Crn) Measurement 
In order to provide an indication of whether Cr had been absorbed by subjects 
undergoing CrH20 supplementation plasma Cm was tested from a 30 ~ fingerprick 
blood sample. A Reflotron Photochemical Analyser was used to measure blood 
creatinine levels from spectrophotometry before supplementation and again just before 
the final strength test. The rationale for the use of plasma Crn for this purpose has been 
described by Willoughby and Rosene (2001). 
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3.3 Statistical Analysis 
All statistical analyses were carried out using SPSS for windows release 10.0 and the 
accepted level of significance was set at p $ 0.05. Column graphs were prepared using 
Microsoft Excel 97. DEXA scans were analysed using a Hcst for whole body data It 
was decided that a t-test was appropriate as there were only two sets of means in each 
mass test, those being the test done before the implementation of the supplementation 
and training programme, and those tests taken afler the 12 week protocol and only 
change scores were examined. Limb segment data was analysed using a one way 
analysis ofvariance to test the null hypothesis. 
As in the total body mass data, only fat free mass and fat mass were used for the present 
study. However because each limb segment was treated as a separate group there were 
more mean scores and so the t-test used for the whole body data was discarded in favour 
of a one-way ANOVA for the limb segment data. 
Isometric and Isokinetic tests were analysed using a 2-way ANOV A with repeated 
measures on one factor (time} (Newton metres). There were four groups cr~:atinc and 
training (CrT}, creatine and not training (CrU), placebo and training (PIT) and placebo 
and not training (PIU) and four test :sessions baseline (BL) and \\-'ccks 2, 7 and 12 
Similarly, the endurance test data consisting of total work done in the five endurance 
sets were analysed using a Repeated Measures ANOV A. 
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CHAPTER FOUR 
Results 
4.1 Training 
Figure 5 shows the average training volume for the two groups derived from the 
training records kept by the subjects. Total training volume was detennined by 
multiplying the number of repeti!ions by the number of sets by the weight used on each 
occasion to obtain a work done for each training session. Data for each session was 
summed to obtain a total work done, or training volume. All subjects started at the 
same training volume, which was set at 12 repetitions (1 set) with a cuff weight of 3 kg 
(this was verified as an appropriate weight at the baseline test). Subjects were 
instructed to increase the repetitions, sets and weight on a weekly basis as the exercises 
became easier. The total training volumes of the creatine and placebo groups were 
similar over the 12 week programme (Figure 5). The creatine group performed an 
estimated mean total work of 8,369 J (± 3089 (sem)) compared to the placebo group 
value of8,799.5 J (± 9492), the difference between the groups being approximately 5%. 
Mean increases in weekly training load from week 1 to week 12 were also similar for 
the creatine and placebo groups(+ 45 %). From analysis of the training diaries. and 
assuming that they represent an accurate record of training activities of the individuals 
concerned, subject adherence to the programme was good. Thus, the creatine group 
missed a total of 19 sessions (out of 180) or about 10%, compared to the placebo group 
value of26 missed sessions out of216 (approximately 12%). 
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Figure 5. Total training load over 12 weeks for the Cr (n = 5) and PI (n = 6) groups 
(mean ± sem). Load was calculated as a product of repetitions x sets x weight for each 
individual . 
4.2 Plasma Creatinine 
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Figure 6 Mean Plasma Creatinine. Plasma creatinine concentration pre and post 
supplementation/training for Cr (n = S) and PI (n = 6). Results are mean ± sem. 
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Figure 6 illustrates the average plasma creatinine for the two groups at baseline and 
week 12. The normal range for blood creatinine for males is 53 - 97 Jlmol/1.... Both 
groups had similar levels at baseline, although the creatine group showed an increase 
following supplementation (20.2%), as did to the placebo group (11.2%). Neither the 
extent of the increases over time nor the differences in creatinine concentrations 
between groups were statistically significant. 
U Body Composition 
Table 2 shows the Baseline (BL) and Week 12 (Wk !2) DEXA scan results for body 
weight, total lean body mass and percentage body fat mass for both the groups. The 
means for the two groups were similar at baseline. although the creatine group was 
slightly heavier on average and had a slightly higher body fat content. There were no 
significant alterations in total body mass measures over the twelve weeks of the study 
for either group. Similarly the lean body mass remained unchanged for both groups. 
Fat mass measures were not significantly different from BL to Wk 12 for either group. 
Table 2. Whole body DEXA results showing total body weight and lean tissue mass in 
kilograms and percentage of fat mass before and after the programme 
Grp n Body Weight (kg) Lean Body Mass (kg) Fat Mass(%) 
BL Wkl2 BL Wk12 BL Wk !2 
Mean (sem) Mean (sem) Mean (sem) Mean (sem) Mean (sem) Mean (sem) 
Cr 5 83.62 (4.4!) 83.80 (4.53) 72.55 (2.46) 7222 (2.50) 24.12 (!.86) 24.52 (!.53) 
PI 6 79.96(3.88) 8033(4.28)73.58(4.56) 73.63(3.75) 22.83(4.50) 22.80(3.72) 
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M Limb Segment Mass 
The total lean mass for each upper limb volume cursored from individual DEXA scans 
is reported as segmental lean mass. Segmental fat mass is expressed as a percentage of 
total mass for the limb volume of interest. The mean results for each sub-group of 
limbs are summarised in Table 3 (an example of a DEXA scan is included in Appendix 
D). Again the two groups were non-significantly different at the beginning of the 
investigation. As seen in the total body composition data, there were no notable changes 
in limb composition associated with either ingestion ofCrH20 or training. 
Table 3 Limb segment DEXA results showing segmental body weight and Jean tissue 
mass in kilograms and percentage of fat mass before and after the programme. 
Group Limb Segmental Lean Mass (kg) %Fat Mass 
BL 12 BL 12 
Mean (sem) M~an (sem) M~!!O (sem} Mean (seml 
-
Creatine Trained 6.38 (0.38) 6.67 (0.23) 24.34 (2.84) 24.72 (3.28) 
Untrained 6.40 (0.37) 6.59 (0.31) 24.84 (3.34) 25.42 (3.26) 
Placebo Trained 6.28 (0.31) 6.50 (0.37) 23.38 (3.62) 23.43 (3.27) 
Untrain!i:d 6,37 (0.37) 6.53 (0.39) 22,95 (4,05) 23.07 (4 09) 
!..~Baseline Strength 
On analysis of the data, it was found that the tendency for change for the knee flexors 
was similar to those of the knee extensors. Therefore, in order to minimise the amount· 
of extraneous data presented, it was decided to display only the knee extensor results for 
the muscle function assessments. Individual and group findings for all muscle function 
parameters are included in Appendices E and F. 
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Figure 7. Baseline data for isometric and isokinetic strength at 60°/sec, 180°/sec and 
240°/sec for CrT (n = 7), CrU (n = 7), PIT (n = 7), PIU (n = 7). Results are mean± sem. 
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Figure 8. I so kinetic peak torques at 60, 180 and 240° /sec expressed as a percentage of 
isometric 60 degrees at baseline for CrT (n = 7), CrU (n = 7), PIT (n = 7) and PlU (n = 
7). Results are mean ± sem. 
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Isometric maximal voluntary knee extensions were perfonned at three angles of knee 
flexion (45, 60 and 75 degrees). Responses over time were similar for each angle, with 
the greatest strengths produced at the mid-range value. Only data at 60 degrees of knee 
extension will be presented in this section (all data are shown in Appendices E and F). 
Baseline values (mean± sem) for isometric strength were similar between the trained 
and untrained limbs for each group (CrT= 140.9 Nm (± 14.6) vs CrU = 1317 Nm (± 
10.9)). Isometric strength at baseline was also non-significantly different between 
groups, although the PI group was slightly stronger than the Cr group (PIT= 162. I Nm 
(± I L4) vs PIU = 166.6 NM (± 15.7)). On average the placebo group was 
approximately 16% stronger than the creatine group. Similar trends between groups 
and sub-groups were also seen for isokinetic peak torque values (Figure 7). Baseline 
isokinetic strength results were similar between groups, although the placebo group 
were, on average, slightly stronger than the creatine group at each of the three velocities 
tested (approximately 16% at 60°/sec, 19% at 180°/sec and 13% at 240° /sec). When the 
voluntary torque data at each velocity are expressed as a percentage of isometric torque 
(Figure 8) it can be seen that the creatine group were able to generate a slightly higher 
proportion of their isometric torque at each of the testing velocities compared to the 
placebo group. The observed differences averaged 3-10%, but were not significant for 
any ofthe limb groups tested. 
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1.6 StrenBth Changes Over Time 
4.6. I JsomeJric StrengJb 
Responses over time were similar for each angle therefore values for 60 degrees only 
are presented in this section (all normalised and raw data for extensors are given in 
Appendix E and flexors in Appendix F). 
Overall, there was a significant effect for time (p::;; 0.01) on isometric strength and post 
hoc analysis showed the difference was due to week 7 vs baseline (p ~ 0.01) and week 
12 vs baseline (p :5 0.01). Figure 9 illustrates that the CrT group improved their 
isometric strength at this angle by 19% at week 7 and 15% at week 12. The PIT group 
also experienced some improvement (1 0% and 11% at weeks 7 and 12 respectively). 
4.6,2 lsokinetic streogJh 
At a velocity of 60°/sec the interaction for training and group produced a non~ 
significant p value of 0.059. There was a significant main effect for time (p = S 0.01 ), 
and post hoc analysis showed the differences to be due to week 7 vs baseline (p S 0.01 ). 
Thus, the CrT group had a greater improvement in strength at this velocity than all the 
other groups at week 7, equating to a 20% strength gain at week 7 (Figure 10). The PIT 
group saw an improvement of 14% at this time point. whilst the CrU group improved by 
some 10%. 
Figure 11 illustrates the changes in peak torque at 180°/sec over the course of the 
exercise programme. There was a significant time effect in this case, with post hoc 
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analysis showing the differences to be week 2 vs baseline (p < 0.05), week 7 vs baseline 
(p < 0.05) and week 12 vs baseline (p < 0.05). A between groups analysis showed no 
significant differences. Both the creatine (CrT and CrU) and the placebo trained (PIT) 
groups saw some improvement in the amount of torque they were able to generate 
compared to the PIU group during the course of the study. The CrT group improved by 
only 8% at week 2 while the CrU group improved by 21% and the PIT group improved 
by 14%. The largest changes were seen at week 7. The CrT group improved 23% at 
week 7 compared to 32% for the CrU (both increases were significant compared to 
baseline values) and 19% for the PIT. At week 12 the CrT group were 11% higher than 
their baseline value, the CrU group scored 21% higher than their baseline and the PIT 
group improved by week 7 to 22% above baseline. 
For the fastest testing velocity (240°/sec) the normalised data is represented in figure 12. 
The interaction for training and group produced a non-significant p value of0.07. There 
was however a significant main effect for time (p ::; 0.05). Post hoc analysis showed the 
effect for time was due to week 2 vs baseline (p S .0.05). week 7 vs baseline (p :5 0.05) 
and week 12 vs baseline (p 5 0.05). This shows that the training was the main cause of 
the improvement as both training groups experienced a similar improvement across time. 
The largest changes seen for this speed were at week 7 with the CrT group Improving 
by 23%, the CrU group by 23% and the PIT group by 23% compared to their baseline 
strength. 
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Figure 9. Isometric strength changes over time expressed as a percentage of baseline 
values for the four limb groups (mean± sem). 
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Figure 11. Isokinetic Strength (180°/s) changes expressed as a percentage of baseline 
peak torque values for the four limb groups (mean ± sem). * = p <0.05 compared to 
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torque scores for the four limb groups (mean ± sem) .. 
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UEndurance 
The average total work done for each of the limb group over five sets of fifteen 
maximal voluntary contractions (MVCs) at 180°/sec of the endurance task is shown in 
figure 13. The group means for this test were similar for the CrT, CrU and the PIT 
groups at baseline, however, the PlU group was able to generate 13% more work 
volume than the other three groups at baseline (although this difference did not prove 
statistically significant). When the endurance tasks were repeated, the CrT group 
showed the greatest improvement in total work and this is most noticeable at week 7 
compared to baseline. The CrT group improved by 14% over baseline at week 2 and 
perfonned 21% more work at week 7 compared to the initial test. These improvements 
in total work were not maintained in this group, and by week 12, the work generated by 
the CrT group during the endurance task had declined somewhat (although it remained 
significantly improved (14%) compared to the baseline value). The effect of training in 
the absence of creatine ingestion (PIT group) resulted in improvements of9% and 11% 
at week 2 and week 7 respectively, and this increased to 14% more work than baseline 
at week 12. The interaction for training and group produced a non-significant p value of 
0.057. There was a significant main effect for time (p :S 0.05), and post hoc analysis 
showed the effect for time was due to a difference in week 2 vs baseline (p :S 0.05), 
week 7 vs baseline (p $ 0.05) and week 12 vs baseline (p $ 0.05). There was a 
significant interaction for training and time (p :S 0.05) and post hoc analysis showed the 
difference was due to week 7 vs baseline (p $ 0.05). 
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Figure 13 Total Work for extensors over the endurance task for the four limb groups 
(mean ± sem). * = p :::;0.05 compared to baseline. 
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CHAPTER FIVE 
Discussion 
ll Effects ofcrearine supplementation 
Although it is clear that negative changes in muscle oxidative capacity and strength 
occur in older individuals, the ex~ent to which these changes are related to the effects of 
reduced activity compared to ageing per se are under debate (Kent~Braun et al., 2000; 
Frontera et al., 2000). Since it is has been documented that, with advancing age, muscle 
creatine and phosphocreatine levels become reduced, the use of creatine 
supplementation to enhance the levels of these agents seems a logical proposition 
(Chrusch et al., 2001; Rawson et al., 1999). Indeed, in healthy people aged more than 
fifty years, creatine supplementation has been found to increase resting intramuscular 
phosphocreatine levels and to speed up phosphocreatine resynthesis post-exercise 
(Smith et al., 1998). In the present double-blind study the creatine group showed an 
increase in plasma creatinine levels suggesting that creatine had been absorbed from the 
gut and metabolised (Harris et al., 1992; Kamber et al., 1999; Willoughby and Rosene, 
2001 ). However it is not possible to say whether the creatine had been incorporated 
into the muscle fibres. In order to show whether myofibre creatine absorption took 
place would require multiple muscle biopsy samples. Previous studies of this type have 
yielded generally positive, results for myofibre uptake of creatine with supplementation, 
although with subjects exhibiting large individual variation (Willoughby & Rosene, 
2001; Tamopolsky et al., 2000; Volek et al., 1999; G1eenhaff et al., 1994; Harris et al., 
1992; Annianson et al., 1986). In the present study, subject compliance for ingestion of 
the supplements was very good, with only one subject returning a container with a dose 
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still remaining and no subject reported any adverse side effects during the 
supplementation and training period. Subjects also reported that taking the supplements 
at the appropriate times quickly became part of their daily routine. From the anecdotal 
evidence presented by the subjects in this study, routine supplementation with CrlhO is 
well tolerated without any adverse effects. Previous studies have shown increases of 
muscle total creatine concentration of around 25 to 30% in young subjects following 
ingestion of 20 grams of CrH20 per day (Greenhaff et al., 1994; Rossiter et a! , 1995; 
Casey et al., 1996). Most studies of younger subjects have used dosages of 20-30 g!day 
for loading and approximately 5-7 glday for the maintenance period (Casey ct al., 1996; 
Francaux et al., 2000). Studies of CrH20 supplementation and training in elderly 
populations have used reduced loading dosages of IS glday (Wiroth et al., 200 l) and 
lower maintenance dosages of 4 g/day (Rawson eta!., 1999) with a loading period of 
five to ten days (Wiroth et al., 2001; Rawson et aL, 1999). The rationale for this 
methodology is that older subjects would be expected to have lower levels of muscle 
creatirc than athletes. Rawson et al., (1999) recommended using a longer loading 
period (10 days) for older (greater than 60 years) subjects because they found that 
although the CrH20 may have been absorbed into the blood it did not effect muscle 
mass or strength. Taking this into account, it was decided to use a loading period of 14 
days for the present study. Since the body's creatine requirement is related to muscle 
mass, and older sedentary males generally have a lower muscle mass than younger men 
(Frischknecht, 1998; Fiatarone-Singh, 1998; Young and Skelton, 1994), they would 
theoretically require less CrH20 to achieve optimal loading. 
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5,2 Effects oftraining 
AH subjects were given clear instructions on how to perfonn the training task and asked 
to record the repetitions, sets and weight used as well as number of sets per week in 
their training diary. From these records the amount of work done for each subject was 
calculated and meaned by groups. The training regimen was carefully designed so as to 
be practical for subjects to complete without supervision. It was a home-based training 
regimen and took less than five minutes per day to complete. This was important since 
such an intervention needed to be appropriate for use among an elderly population and 
for patients with muscular degenerative disorders since these individuals may find it too 
difficult or expensive to attend a gym or a clinic on a regular basis. All subjects 
increased their training volume throughout the course of the study by increasing their 
repetitions, sets and cuff weights. Mean increases in weekly traimng load from week 1 
to week 12 were similar for creatine and placebo groups (approximately 45%} and the 
question of whether training alone had a benefit for muscle function can be ad(lressed 
by examining the findings for the placebo training limbs. In this case, there was a trend 
for both isometric and isokinetic strength to increase over the 12 week programme 
(range 1 0-15%} as well as endurance (- 15%} compared to much smaller changes in the 
untrained limb. These changes in muscle function over time did not achieve significant 
levels, nor did any of the measures increase significantly compared to the untrained 
limb in the placebo group. 
A number of reasons could account for the lack of significant changes with training as 
hypothesised. Firstly, the subject dropout in the early stages meant that only 6 subjects 
completed the study in the placebo group. Also, it may he that the training volume and 
intensity were insufficient to show significant improvements in strength and muscle 
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mass for this group. Although subjects were contacted weekly to detennine their 
progress, it was found that individuals were more inclined to increase the number of sets 
rather than the weight lifted. A more regimented protocol for increasing the training 
intensity may have been more appropriate. However, it should be emphasised that an 
important aspect of this study was to provide a training programme that would be 
suitable for sedentary, older subjects. A more aggressive programme might have 
resulted in even greater subject attrition. Perhaps the current protocol would be suited 
to older, frailer individuals or patients with a degenerative muscular disease and future 
research should be directed at these populations using the current experimental model. 
It would also be advisable for future studies to maintain greater control over the training 
regimen in order keep the training load optimal by imposing greater increases in 
workload through increased weight, sets and reps and/or training frequency. In the 
study by Chrusch et al., (2001) subjects were supervised in a gym and encouraged 
directly to increase their workload. These subjects experienced increases in lean tissue 
mass as well as improved strength and endurance of the lower limbs. Other studies to 
show significant increases in mass and strength have also implemented more rigorous 
training protocols and often used younger subjects compared with the current 
investigation (Valek et al., 1999; Kamber et at., 1999; Prevost et at., 1997; Valek et al., 
1997;Balsometal., 1993). 
5.3 Effects of supplementation and training 
Subjects in both groups were given the same training regimen and allowed to progress 
at their own pace. The placebo group had a slightly greater training workload for the 
entire 12 weeks than the creatine group. Thus, there was no evidence to support my 
hypothesis that CrH20 supplementation would enhance the training capabilities of the 
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subjects. None of the subjects who completed the protocol reported illness or injury and 
training diaries show they were training throughout the 12 weeks although some 
subjects missed training sessions. Several studies have been conducted to investigate the 
combination of training and supplementation for reducing the effects of muscle 
degradation and strength loss in elderly people (Chrusch et al., 2001; Rawson et at., 
1999; Berman et al., 1998; Evans, 1992). There have aJso been review articles which 
cover this topic (Fiatarone-Singh, 1998; Fielding, 1995) all of which cite the loss of 
skeletal muscle with advancing age as a major problem among the elderly, and that the 
phenomenon may be reduced with exercise and/or dietary intervention. Apart from 
CrH,O (Chrusch et at., 2001; Rawson et at., 1999; Bennon et at., 1998), other 
supplements which have been used in conjunction with physical activity programmes 
include calcium and vitamin D (Fiatarone-Singh, 1998). 
A number of studies have shom1 that supplementation with CrH20 in conjunction with 
a resistance training programme may promote gains in muscle strength and FFM in 
patients with muscular degenerative diseases (Stout et al., 2001; Tamopolsky et at., 
2000; Walter et at., 1999; Tamopolsky & Martin, 1999). The present study was 
conducted in an effort to add to the body of knowledge regarding possible health 
improvement interventions for the elderly. It has shown that perhaps supplementation 
with CrH20 may have some ergogenic benefit for older populations and can be more 
effective when used in conjunction with a resistance training programme. 
~ 4 Muscle mass 
The present study found no changes in muscle mass for the untrained limbs of the 
creatine and the placebo groups as tested by DEXA, which does not support the first 
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hypothesis. X-ray absorptiometl)' has been shown to he a highly reliable (r ~ 0.99) and 
precise (coefficient of variation of 0.5 - 1.0%) method for the evaluation of individual 
body composition segments, so it is likely that even small increases in muscle mass 
could have been detected (Kreider et al., 1998). Although the creatine group did 
increase their blood creatinine level more than the placebo group, it is possible that the 
supplementation did not increase muscle creatine stores sufficiently to effect a change 
in muscle mass. CrH20 supplementation has been reported to result in an increase in 
total body weight (Earnest et al., 1993; Greenhaff et al., 1994; Volek et al., 1999; 
Francaux & Poortmans, 1999; Becque et al., 2000; Chrusch et al., 2001). When 
creatine is ingested and taken up by muscle an increase in muscle PCr concentration 
results (Harris et al., 1992). This increased concentration of PCr should alter the 
osmolarity of the cell causir.g water to be drawn into the intracellular space thereby 
increasing the volume of the cell and therefore the total muscle mass (Francaux & 
Poortmans, 1999). The lack of any discernible increase in body weight or total lean 
mass is however consistent with previous studies using subjects of similar age (Wiroth 
et al., 2001; Rawson et al., 1999). In young subjects the added creatine seems to have 
the osmotic described, but this uptake does not seem to occur as readily in older people. 
Why older subjects fail to experience the same improvements as young subjects with 
creatine supplementation is not yet clear, however the differences may be related to a 
reduced ability to absorb creatine from the gut or for it to be less readily transported into 
muscle (Rawson et al., 2002). Creatine and its associated phosphotransferase, 
phosphocreatine kinase, aid in supporting high ATP/ADP ratios at equilibrium and the 
maintenance of cellular ATP homeostasis (Harris et al., 1992). Chrush et al., (2001) 
gave elderly subjects a loading dose of 26.4g/day and a maintenance dose of 6.2g!day, 
considerably higher than the present study. This high dosage was chosen as it had been 
used successfully in previous studies to increase muscle PCr levels (Harris et al., 1992~ 
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Hultman et al., 1996). They found significant changes in body composition with an 
increase in lean mass of 5.7% compared to 2.5% in the placebo group, although in this 
study subjects underwent a 12 week supeiVised whole body training programme. This 
is the only study to date that has shown a significant change in muscle mass as a result 
of CrH20 in the elderly. Clearly, more work needs to be carried out into detennining 
the optimal dosing strategies for older populations, and how this should be incorporated 
into a training programme to optimize responses. 
The fourth hypothesis stated that training alone would cause an increase in muscle mass, 
but this was not the case. It is likely that the training stimulus used for this study was 
insufficient to cause an increase in muscle mass. For the reasons already described, a 
light resic;tance programme was purposely designed for this study and it is likely that a 
heavier programme would have yielded changes in muscle mass as well as greater 
increases in muscle strength in these subjects, but would also have been more stressful 
and may have caused muscle soreness. The subjects were given a training load 
approximately 30% of their 1 rep maximum and some subjects quickly found that 
weight to be easily lifted and increased their workload (repetitions, sets and/or weight) 
in the first two weeks of the programme. The increases noticed in the leg strength of 
trained subjects in this study are unlikely related to any change in muscle mass since 
there was no increase in mass shown by segmental DEXA scanning. Furthennore, the 
increases in strength and power output in the first few weeks of a resistance training 
regimen can be largely attributed to adaptations which occur at the neural level (Hurley 
& Roth, 2000). In the study by Chrusch et al., (2001) subjects participated in a 
supervised whoie body training programme conducted three times per week producing a 
much higher workload than the present study. This heavy training elicited no body 
mass changes in the placebo group, the current investigation showed similar fmdings. 
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Another study using a similar training protocol to the present study found the elderly 
subjects did increase their mid thigh circumference by 9% after eight weeks of training 
with weights of 50-80% I RM (Fiatrone et al., 1990). This supports the suggestion that 
in order to achieve appreciable gains in muscle mass subjects require a larger training 
volume than that used in the present study. Also, Fiatarone et aL, (1990) used subjects 
who were considerably older (mean age= 90 years) than those studied by Chrusch et al., 
(2001) (71 years) and in the present study (66 years). Perhaps their lack of physical 
conditioning prior to the study made them more likely to realise a response to the 
training protocol. Although the majority of the subjects in the present study were 
sedentary, two participated in sport (lawn bowls) on a weekly basis and several subjects 
regularly walked on a recreational basis. The subjects in the Fiatarone et al., (1990) 
experiment were not involved in any regular exercise prior to the study and the subjects 
in the Chrusch et al., (2001) study were described as participating in some strenuous, 
moderate and mild physical activity. The training protocol for the current study was 
very easy and simple, and designed to be of practical use as a home based programme 
whereas the protocols used for the Fiatarone et al., ( 1996) and Chrusch et al., (200 I) 
investigations were conducted under supe!Vision by the research teams. This 
investigation was designed to test the efficacy and practicality of a home-based training 
protocol, which could be done safely without the need for expensive equipment or a 
training supe!Visor. 
Hypothesis seven stated there would be a greater increase in muscle mass in the creatine 
group compared to the placebo group with training and this was found not to be the case. 
Previous studies have shown that supplementation with CrH20 in combination with a 
strength training programme caused an increase in lean muscle mass compared to a 
similarly trained placebo group (Chrush et al., 2001; Becque et al., 2000; Francaux & 
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Poortmans, 1999; Earnest et al., 1995; Volek,et al., 1997). Apart from the current study 
the Chrusch eta!., (2001) investigation was the only one to use DEXA scanning to 
quantify muscle mass. Other methods employed to quantify body composition indude 
skinfold tests and a medical scale (Schilling et al., 2000), magnetic resonance imaging 
(MRl) (Welle et al., 1996), hydrostatic weighing (Rawson et al., 1999). Bennon et al., 
(1998) used the Jones & Pearson method to estimate lower limb muscular volume. The 
training protocols used for these studies were gym based and whole body training 
programmes and all except Chrusch et al., (2001) and Bennon et al., (1998) used young 
subjects. Other studies have reported no change in body composition while using 
creatine monohydrate in combination with training (Berman et al., 1998). The subjects 
for the Berman et al., (1998) study were a similar age group to the current investigation. 
As mentioned previously some investigations have shown that creatine loading is more 
difficult to achieve in elderly subjects (Bennon eta!., 1998). The present study showed 
there was no statistically significant change in serum creatinine in the group 
supplemented with creatine monohydrate, both groups were well within nonnal rang~ 
values for pre and post supplementation. For the present study there was very little 
change in lean muscle mass for both CrT and PIT groups, this is in line with previous 
studies using similar age groups (Bennon et al., 1998; Rawson et al., 1999). 
5.5 Muscle strength 
Hypothesis two predicted that the muscle strength of the Cr group would be greater than 
that of the PI group and this was confirmed when Cr was combined with training. The 
findings are consistent with previous studies (Rawson et al., 1999). The isokinetic 
strength of the untrained limbs of the Cr group showed an increase over time at weeks 2 
(21%), 7 (32%) and 12 (21%) at 180°/sec. The PlU group had no significant strength 
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changes throughout the twelve weeks. Possibly, sufficient uptake of creatine was 
achieved to increase strength in the absence of any observable increase in muscle mass. 
It is likely that the effect was related to creatine since the PIU group showed no 
significant improvement in strength (and the study was double-blinded). h is possible 
that the findings relate to improved recovery between contractions during testing since 
87 contractions were made for each test session (including the endurance task). 
Although appropriate rest was allowed (60-120 seconds) for recovery of high energy 
phosphates, it may still have been insufficient for complete recovery. The present study 
also confirmed the findings of Rawson et al., (1999), who did not observe any effect on 
isokinetic strength from CrH20 supplementation alone. 
Interestingly for the strength tests all groups, excluding the PIU group, experienced 
some improvement in strength at all velocities during the course of the investigation. 
This improvement may be due partially to the "learning effect" in which a motor pattern 
is developed in the nervous system and produces a com~ct sequence of muscle 
contractions. During this early training phase there is little or no increase in muscle size 
or strength (Jones et at., 1989). So, even though the training stimulus was small 
compared to other experiments (Fiatarone et al., 1990; Chrusch et al., 2001) some 
benefit appears to have been derived. In the study by Chrusch et al., (2001) the placebo 
group increased their strength during the course of the study possibly because they used 
a gym based, supervised, whole body training protocol, which was enough to elicit a 
muscular adaptation response in the lower limbs. Their training load was many times 
that of the subjects in the present study. The low training stimulus made it more 
difficult to notice the change in strength for these subjects but certainly :;orne 
improvements were made as can be seen in the isokinetic tests (eg, week 7, at 180°/sec, 
CrT improved by 23 and PIT by 19%). In another study (Fiatarone et al., 1990) subjects 
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improved their strength by approximately 177% after 8 weeks using simple knee 
extension exercises. However the subjects were older (average age = 90 years) than 
those involved in the current investigation and were described as "frail, elderly patients" 
(Fiatarone et at., 1990). Possibly this older age group could best benefit from the type 
of light !mining protocol used for the present study. In his review article of 1995, 
Fielding states that studies which used heavier weights and a reduced number of 
repetitions were more effective for evoking muscle strength adaptations than high 
repetitions and lower weights. He further concluded that, in experiments using young 
subjects, weights less than 40% lRM were ineffective for bringing about any increase 
in muscle strength. Anianson et al., (1981) conducted 12 weeks of lower extremity 
exercise in healthy older males using the subjects' own body weight to provide 
resistance and noticed a 9 - 22% increase in isometric and isokinetic peak torques of 
knee extensors. Another investigation involving older males (mean age 70 years) 
employed an 8 weeks training protocol of the elbow flexors at 66% 1RM and noted a 
23% isometric strength increase (Moritani and De Vries, 1980). More recently Frontera 
et at., (1988) used a knee flexion and extension protocol at 80% of 1 RM and found a 
107% increase in extensor strength and a 226% increase for flexors. 
Hypothesis eight stated that the strength gain of the creatine group would be greater 
than that of the placebo group with supplementation and training. The CrT group did 
improve during this study, particularly at week 7 (approximately 25% for an velocities). 
although this was not significantly greater than the improvement or_the PIT group 
(approximately 19%). At week 12 the PlT group continued to improve in strength 
whilst the CrT group had declined slightly. The reasons for the decrease in strength 
between weeks 7 and 12 are not clear. It may be due to a lack of motivation, as this was 
a long training protocol with little supeJVision, or possibly reduced effectiveness of 
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supplementation over time. Perhaps the strength measurements were not a true 
reflection of their strength capabilities as their training in the final few weeks was 
consistent according to their diaries. In the study by Chrusch., et a1 (2001) the creatine 
group improved their strength more than a placebo group for the lower limbs. Casey et 
al., (1996) showed that with repeated bouts of maximal isokinetic cycling improved 
ATP resynthesis increased PCr levels causing an enhanced perfonnance. No such effect 
was observed in the present study. It is possible that Cr may not have been completely 
taken up by the muscles in the creatine supplemented group and although they improved 
their strength slightly more than the placebo group at weeks 2 and 7 the differences 
were insignificant. Perhaps greater numbers of participants would have shown a 
difference. 
5.6 Muscular endurance 
The third hypothesis stated that there would be a positive change in the endurance of the 
untrained limb of the creatine group compared with that of the untrained placebo group. 
This was not the case since both untrained (creatine and placebo) groups had similar 
endurance capacities throughout the study. It was expected that the creatine group 
would show some improvement in endurance, particularly in the final sets. The 
rationale for this comes from previous work on the effects of creatine supplementation 
on eddurance pelfonnance. Prevost et al., (1997) who used a maximal cycling protocol, 
showed that creatine supplementation significantly improved the capacity to maintain 
high intensity intennittent exercise. Also, Kamber et al., (1999), using repeated 30 s 
Wingate testing found that young subjects improved over the final few bouts compared 
to a placebo condition. Chrusch et al., (2001) found an improvement in quadriceps 
endurance for a creatine group compared with a placebo group undergoing similar 
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training protocols. It is interesting to note that this study also had subjects perfonn a 
bench press training and testing protocol and found no difference between the groups in 
endurance for the upper body exercise task. Rawson et al., (1999) showed an 8% 
increase in muscular endurance of quadriceps using five sets of 30 MVC repetitions 
following 10 days of supplementation with CrH20 in elderly males. A Cybex 6000 
isokinetic dynamometer was used for the present study to test muscular endurauce, and 
the testing protocol was 15 MVC repetitions x 5 sets, with 30 seconds recovery between 
sets. This protocol was preferred to a cycle ergometer test because it allowed the testing 
of each leg separately, enabling comparison of trained and untrained limbs for each 
subject. In the final sets, as the subjects fatigued it was hoped the extra stored PCr in 
the supplemented group would enhance the capacity of muscles to resynthesise ATP 
and thereby maintain greater power output. Although Rawson et al., (1999) used twice 
the repetitions of the present study for this test the quadriceps muscles were not 
subjected to a strength test prior to the endurance test so for the present investigation it 
is possible that the subjects were partially fatigued at the start of the endurance test. 
Since subjects were given appropriate rest between strength tests and prior to the 
endurance test it is thought that this is unlikely. In the final sets, as the muscles fatigued 
it was hoped the extra stored phosphocreatine would give more support allowing the 
muscles to generate a greater force. This was not the case for the present investigation. 
Perhaps the dosage for this group was too low. It was thought that because elderly 
males generally have lower muscle mass than athletes for whom high doses are 
recommended, the lower dose combined with an extended loading period would 
increase PCr stores in the muscle enough to support extra work at the end of the 
endurance test. For future studies a higher loading dose combined with an extended 
loading period may be required to increase muscle PCr stores for the elderly. The 
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present study found no negative side effects, so an increased dose for a longer time 
frame should not create major problems in this respect. 
The sixth hypothesis stated that there would be an increase in total work during an 
endurance task with training alone. This was not shown in this study. The placebo and 
training group improved their endurance only slightly at week 2 and were close to 
baseline at weeks 7 and 12. Again it is possible that the training was not sufficient to 
stress the muscles enough to improve muscular endurance for this group. The tests 
were 5 sets of 15 repetitions at maximal effort and the training was approximately 12 to 
15 repetitions, 1 to 3 sets at 30% maximal effort. The subjects were told to take no rest 
between sets for the present study, ie do one set of extensors, then immediately do 
flexors then extensors again and so on. Effectively this gives the muscle approximately 
30 seconds to rest while the opposite muscles are being worked. The instructions given 
to the subjects were such that their training would be carried out at approximately 
180°/second, (the speed used for the endurance test) and all subjects reported that the 
endurance test was much harder than the training. They were told to count during the 
training in order to keep the appropriate cadence, a]though this may have varied 
between subjects and training sessions. Perhaps a training regimen, which was more 
specific to the endurance test would have shown a larger improvement in petfonnance. 
In the Chrusch et al., (2001) study the subjects in the placebo group conducted a whole 
body, training regimen, which was more rigorous than the present investigation. 
Although the training volume was not as high and the improvement was not as 
significant as the creatine group, the subjects did notice a significant improvement in 
endurance during the course of the investigation for leg extension and leg press but not 
for bench press. The difference between the current investigation and the Chrusch et al., 
(2001) study is the subjects' training volume. In the study by Bermon et al., (1998) the 
participants were older adults who were tested using leg extension, leg press and chest 
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press. Although the testing protocol for this investigation did not have a repeated bouts 
endurance component, it did look at a 12 RM test for the above exercises. Bennon et al., 
(1998) found a significant improvement for the three test protocols for the trained 
placebo group. This improvement was similar to that of the training group 
supplemented with CrH20. This investigation also used a greater training volume than 
that of the present study, which, as already discussed, may have been an important 
factor in explaining my findings. Studies, which have used training loads of 
approximately 80% IRM, have noticed more significant changes in strength and 
endurance than the current investigation (Chrusch et a1., 2001; Bennon et al., 1998; 
Fielding, 1995; Fiatarone, et al., 1990). Wiroth et al., (2001) found that fatigue was 
delayed significantly in lO seconds of repeated bouts cycling and this could have 
implications for lower intensity, longer duration activity such as non-stop cycling or 
walking. Having said this, the rationale behind this training protocol should be re-
emphasised, that it should be a home-based training programme that does not require a 
supeiVisor or expensive training equipment. For this reason the subjects were all started 
at a given weight and allowed to progress at their own pace. 
Hypothesis nine stated that endurance in the creatine group would be greater than the 
placebo group with training. The CrT group improved their endurance significantly at 
weeks 2 (14%), 7 (21%) and 12 (14%). The PIT group also improved their endurance 
scores although not as much as the err group at weeks 2 (9%) and 7 (II%) despite a 
greater training volume. The two groups were however, the same at week 12 due to the 
drop in endurance scores by the CrT group at the final testing session. From this it is 
possible to conclude that supplementation with creatine supported extra work in the 
endurance tests. During short-tenn maximal-intensity exercise ATP is depleted and 
then regenerated by hydrolysis of PCr stored in the muscle. Previous studies have 
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shown that oral supplementation with creatine monohydrate can increase PCr stores in 
the muscles, which can then add further support to the production of ATP (Casey ct al., 
1996; Valek et al., 1999; Greenhaffet al., 1994; Harris ct al., 1992). This added PCr 
availability works to enhance the endurance capability of the muscles at high intensity 
repeated bouts. Prevost et al., (1997) suggested that, in activities where intennittent 
bursts of maximal or near maximal effort are required, creatine supplementation may be 
of benefit by allowing individuals to perfonn at a higher intensity or to recover more 
quickly following activity. It is this idea that also fonns the basis of the rationale for the 
present study. If supplementation with CrH20 can support extra effort in the elderly, or 
people with a degenerative muscular disease in the same way as for athletes, then daily 
tasks may be able to be carried out more quickly and efficiently and with a reduced risk 
of injury due to falling. Elderly people may be at or near a "functionally-important 
strength-related threshold" and changes in the ability of the cardiovascular and muscular 
systems to support perfonnance of daily tasks can reduce an individuals' quality of life 
(Young & Skelton, 1994; Fielding, 1995). Results from the present study support the 
concept ofincreased endurance in repeated bouts, although many of the previous studies 
used cycle ergometry to test for endurance in repeated bouts of maximal exercise 
(Balsam et al., 1993; Wiroth et al., 200 I). 
5.7 Conclusions and Recommendations for future research 
The present study has shown that, despite a limited subject population, a moderate 
home-based resistance training protocol combined with CrH20 supplementation can 
have a positive effect on muscular endurance. Although there were minimal 
improvements in isometric or isokinetic maximal strength or total body and limb 
segment mass compared to the other groups, the tendency suggest some beneficial 
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effects of combined training/supplementation with CrH20. Thl the results of this 
investigation support one of the nine hypotheses put forward and report the major 
finding of the study to be that oral supplementation of CrH20 combined with a light 
home based training programme can improve endurance in repeated bouts of maximal 
voluntary exercise. Perhaps a larger subject pool could have elicited clearer information. 
The low number of individuals who completed the protocol made it difficult to show a 
statistically significant difference between the groups. Further research is required 
however, as to the potential use of CrH20 in the very old, people with degenerative 
muscular diseases and women. Some studies have already been carried out with 
positive findings for supplementation with CrH20 in the elderly (Chrusch et al., 2001; 
Rawson eta!., 1999; Bermon eta!., 1998), pathological groups (Stout ct al., 2001; 
Tamopolsky et al., 2000, Tamopolsky eta!., 1999;) and womon (Hamilton et al., 2000). 
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APPENDIX A 
ThWORMEDCONCENTFORM 
The effects of creatine monohydrate supplementation and 
training on skeletal muscle mass. strength and endurance in older males. 
I am doing research on muscle strength training, could you please take a couple of 
minutes to read this. 
The purpose of this study is to investigate the responses of muscle to strength training 
while taking a dietary supplement. 
You will be asked to perfonn a series of strength tests. Both, strength at certain angles, 
pushing against an immovable object and strength in moving the lower leg will be 
tested. Other tests include a type of x-ray and a finger prick blood sample. X-rays will 
be taken of each thigh and will take approximately half an hour in total. These will be 
carried out before supplementation and training begins, and again at week 12. Training 
will consist of lifting the foot with an ankle cuff to provide weighted resistance. As an 
increase in the ease of training is noticed, the weight will be increased slightly. Training 
will be conducted three times per week for twelve weeks. 
During the tests you will be lifting and lowering your foot as fast as you can four times. 
Each test will last only a matter of a few seconds with the exception of one test, which 
takes approximately 135 seconds. The entire procedure will take not more than one hour. 
For any reason you wish to stop the test session, we will stop. Testing will be done 
before the start of training and supplementation and re-tests will occur at weeks 2, 7, 
and 12 Tests will be carried out at Edith Cowan University, Joondalup. 
It is hoped that this research will :1elp reduce the incidences and effects of falls in the 
elderly, and will also go a long way to improving the lifestyle of this population by 
making them more able to enjoy physical pursuits. 
For the purposes of this study you will receive free health checks, strength assessments 
and professional fitness and nutritional advice. 
I understand that I am free to withdraw from this study at any time. 
I acknowledge that I have read the above statement, which e:-.-plains the nature of the investigation and the 
statement has been explained to me to my satisfaction. Before signing this document I have been given 
the opportunity to ask any questions relating to the study and I have received satisfactory answers. I agree 
that research data gathered from the result of the study may be published provided my name is not used. 
~ ...................................... . . .... , aged .......... yrs, agree to participate as a 
subject in the study described above. 
Signed............................................. Date ................ . 
For further infonnation please contact Andrew Lavender on 93626024 or Dr Paul Sacco 
on 94005642. 
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APPENDIX B 
Health Screening Questionnaire 
The Effed of Creatine Monoliydrate Supplementation and 
Training on Skeletal Muscle Mass and Strength in Older Males. 
!nvestigaJor Andrew Laycnder BSc 
For this study you will be asked to attend a health screening with our campus Doctor. To assist with this 
check up we would like you to answer the following questions. 
Conunon SCtl!".C is )'Our best guide when you answer these questions. Please read the questions carefully 
and answer each one honcstJy: check yes or no. 
YES NO 
I. Has your doctor c\'cr said you ha\'c a heart condition and that you 
should on1y do physical activity rcconuncndcd by a doctor? 
2. 
3. 
4. 
5. 
6. 
1. 
8. 
9. 
10. 
Do you feel pain in your chest when you do physical activity? 
In the past month hm·c you had chest pain when you were not 
doing any physical acti\'ity? 
Do you lose balance because of dilljncss or do you ever lose 
conciousncss? 
Do you h:1ve a bone or joint problem which may limit your 
ph~1;ical activity'! 
Is your doctor currently prescribing drugs for your blood pressure 
or heart condition? 
Arc you a Yegetarian? 
Do you drink coffee or tea'! How much? ... cups/day. 
Do you drink alcohol:' How much? ..... drinks/day. 
Do you know of any other reason why you should not do physical 
acti\"ity? 
I have read. understood and completed this questionnaire. Any questions I had were answered to my full 
satisfaction. 
NaJnC ............................................. .. Witness .......................... . 
Signature ......................................... . Date ............................... . 
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APPENDIX E 
(Knee Extensor Muscle Function Data) 
81 
CREATINI! 112met[jc zs. 6Q, gsjtg 
Isometric trained (75deg) Isometric untrained (75deg) 
BL 2 7 12 BL 2 7 12 
1 140 142 167 171 1 122 148 157 114 
2 24:3 236 218 216 2 208 167 220 164 
3 10;~ 107 148 146 3 119 138 148 149 
4 159 197 203 161 4 121 145 122 125 
5 159 159 175 145 5 138 152 136 146 
6 108 141 6 121 126 
7 188 202 199 7 194 174 195 
mean 167.00 169.14 185 167.8 mean 145.86 150.00 163.00 140.00 
sd 48.44 44.38 26.08 29.05 sd 37.69 16.42 37.27 20.14 
sem 18.31 16.78 10.65 12.99 sem 14.25 6.21 15.21 9.01 
Isometric trained (75deg) Isometric untrained (75deg) 
BL 2 7 12 BL 2 7 12 
1 100 101 119 122 1 100 121 129 93 
2 100 97 90 89 2 100 81 107 80 
3 100 105 145 143 3 100 116 124 125 
4 100 124 128 101 4 100 120 101 103 
5 100 100 110 91 5 100 110 99 107 
8 100 131 8 100 104 
7 100 107 106 7 100 90 101 
mean 100 109.34 116.28 109.32 mean 100 106.02 109.96 101.76 
sd 0 12.81 19.09 2!.02 sd 0 15.46 13.20 16.90 
sem 0 4.84 7.79 10.29 sem 0 5.84 5.39 7.56 
PLACEBO 
Isometric trained (75deg) Isometric untrained (75deg) 
BL 2 7 12 BL 2 7 12 
8 191 220 232 214 8 250 278 266 114 
9 133 144 122 130 9 99 126 117 164 
10 151 184 174 122 10 160 183 157 149 
11 122 127 137 138 11 160 168 193 125 
12 213 207 175 168 12 216 187 212 148 
13 188 159 179 218 13 179 160 172 
14 175 213 14 179 207 
mean 167.57 179.14 169.83 165 mean 177.57 187 186.17 140 
sd 33.25 36.46 38.36 42.5 sd 47.47 47.45 50.84 20.1 
sem 12.57 13.78 15.66 17.34 sem 17.94 17.93 20.75 9.01 
Isometric trained (75deg) Isometric trained (75deg) 
BL 2 7 12 BL 2 7 12 
8 100 115 121 112 8 100 111 106 46 
9 100 108 92 98 9 100 50 47 66 
10 100 122 115 81 10 100 73 63 60 
11 100 104 112 113 11 100 67 77 50 
12 100 97 82 79 12 100 75 85 59 
13 100 85 95 116 13 100 64 69 
14 100 122 14 100 83 
mean 100.00 107.55 103.02 9~.75 mean 100.00 74.80 74.47 56.00 
sd o.oo 13.61 15.49 16.68 sd 0.00 18.98 20.34 1.05 
sem 0 5.14 6.32 6.11 sem 0.00 7.17 8.30 3.60 
82 
CREATINE 
Isometric trained (60deg) Isometric untrained (60deg) 
BL 2 7 12 BL 2 7 12 
1 126 140 160 157 1 125 151 146 161 
2 191 210 214 187 2 170 168 203 183 
3 63 100 115 119 3 107 118 126 134 
4 148 170 182 167 4 121 129 122 130 
5 148 136 157 145 5 136 129 148 155 
6 108 140 6 100 113 
7 182 161 193 7 174 165 198 
mean 140.86 151.00 170.17 155.00 mean 133.29 139.00 157.17 148.60 
sd 38.64 34.18 34.36 25.34 sd 28.96 22.28 35.17 15.50 
sem 14.60 12.92 14.03 11.33 sem 1G.95 8.42 14.36 6.93 
Isometric trained (60cleg) Isometric untrained (60deg) 
BL 2 7 12 BL 2 7 12 
1 100 111 127 125 1 100 121 117 129 
2 100 110 112 98 2 100 99 119 96 
3 100 120 139 143 3 100 110 118 125 
4 100 115 123 113 4 100 107 101 107 
5 100 92 106 98 5 100 95 109 114 
6 100 130 6 100 113 
7 100 88 106 7 100 95 114 
mean 100 109.48 115.78 115.34 mean 100 105.60 112.90 114.26 
sd 0 14.78 13.00 19.26 sd 0 9.88 6.99 13.38 
sem 5.22 4.91 7.86 sem 3.74 2.64 5.06 
PLACEBO 
Isometric trained (60deg) Isometric untrained (60deg) 
BL 2 7 12 BL 2 7 12 
8 209 216 255 209 8 236 251 226 258 
9 115 142 136 132 9 118 115 107 110 
10 160 164 176 178 10 163 160 160 164 
11 140 121 145 155 11 190 155 180 175 
12 172 161 175 167 12 171 156 170 206 
13 171 157 178 209 13 174 160 157 174 
14 168 176 14 114 161 
mean 162.14 162.43 177.50 178.33 meln 166.57 168.29 166.67 182.60 
sd 29.22 29.50 41.94 30.49 sd 41.99 41.37 38.49 54.56 
sem 11.04 11.15 17.12 12.45 sem 15.87 15.64 15.71 22.27 
Isometric trained (60deg) Isometric untrained (60deg) 
BL 2 7 12 BL 2 7 12 
8 100 103 122 100 8 100 106 96 109 
9 100 123 118 115 9 100 97 91 93 
10 100 103 110 111 10 100 110 98 101 
11 100 86 104 111 11 100 82 95 92 
12 100 94 102 109 12 100 91 99 120 
13 100 92 104 122 13 100 92 90 100 
14 100 105 14 100 141 
mean 100.00 100.85 109.95 111.28 mean 100.00 102.89 94.83 102.62 
sd 0.00 12.10 8.45 7.30 sd 0.00 19.48 3.78 10.71 
sem 0 4.57 3.45 2.98 sem o.oo 7.36 1.54 4.37 
8} 
CREATINE 
Isometric trained {45deg) Isometric untrained (45deg) 
BL 2 7 12 BL 2 7 12 
1 114 114 142 130 1 107 119 126 148 
2 168 165 197 157 2 130 129 164 136 
3 65 80 92 96 3 83 107 111 108 
4 100 145 134 136 4 102 103 103 119 
5 117 100 123 126 5 122 115 122 130 
6 102 114 6 84 103 
7 134 122 172 7 148 133 163 
mean 114.29 120.00 143.33 129.00 mea~ 110.86 115.57 131.50 128.20 
sd 31.79 28.07 36.98 21.98 sd 24.02 12.15 26.08 15.40 
sem 12.02 10.61 15.10 9,83 sem 9.08 4.59 10,65 6.89 
Isometric trained (45deg) Isometric untrained (45deg) 
BL 2 7 12 BL 2 7 12 
1 100 100 125 114 1 100 111 118 138 
2 100 98 117 93 2 100 99 126 105 
3 100 123 142 148 3 100 129 134 130 
4 100 145 134 136 4 100 101 101 117 
5 100 85 105 108 5 100 94 100 107 
6 100 112 6 100 123 
7 100 91 128 7 100 90 110 
mean 100 107.80 125.14 119.77 mean 100 106.73 114.79 119.26 
sd 0 20.68 12.81 21.88 sd 0 14.69 13.62 14.69 
sem 0 7.81 5.23 9.78 sem o.oo 5.55 5.56 6.57 
PLACEBO 
Isometric trained (45deg) Isometric untrained (4Sdeg) 
BL 2 7 12 BL 2 7 12 
6 199 217 231 214 8 188 207 187 216 
9 80 122 111 110 9 95 88 89 103 
10 125 129 141 151 10 133 1=:.8 125 129 
11 121 115 129 138 11 182 132 152 153 
12 146 108 133 148 12 149 138 159 183 
13 136 137 144 171 13 141 136 132 148 
14 129 138 14 88 130 
mean 133.71 138.00 148.17 155.33 mean 139.43 138.43 140.67 156.8 
sd 35.50 36.53 42.21 35.0 sd 38.57 35.03 33.47 44.4 
sem 13.42 13.81 17.23 14.28 sem 14.58 13.24 13.66 18.11 
Isometric trained (45deg) Isometric untrained (45deg) 
BL 2 7 12 BL 2 7 12 
8 100 109 116 108 8 100 110 99 115 
9 100 153 139 138 9 100 93 94 108 
10 100 103 113 121 10 100 104 94 97 
11 100 95 107 114 11 100 73 84 84 
12 100 74 91 101 12 100 93 107 123 
13 100 101 106 126 13 100 96 94 105 
14 100 107 14 100 148 
mean 100,00 92.93 96.89 102.71 mean 100.00 102.26 95.16 105.36 
sd 0.00 42.77 42.16 41.73 sd 0.00 23.22 7.66 13.63 
sem 0 16.17 17.21 17.04 sem 0.00 8.78 3.13 6.56 
ltoklnet!c &Odeafteo 
CREATINE 
lsokinetic trained 
1 
2 
3 
4 
5 
6 
7 
BL 2 
111 
178 
118 
107 
102 
99 
149 
113 
176 
108 
125 
102 
80 
134 
7 
134 
184 
111 
133 
126 
153 
12 
123 
161 
127 
119 
108 
mean 123.43 119.71 140.17 127.20 
sd 29.27 30.20 25.40 20.5 
sem 11.06 11.42 10.37 9.16 
lsokinetic trained 
1 
2 
3 
4 
5 
6 
7 
BL 2 7 12 
100 101.80 120.72 110.81 
100 98.88 103.37 90.45 
100 91.53 94.07 107.63 
100 116.62 124.30 111.21 
100 100.00 123.53 103.92 
100 80.81 154.55 
100 89.93 
mean 100.00 97.11 120.09 104.80 
sd 0.00 11.33 20.85 8.5 
sem 0 4.28 8,51 3.82 
PLACEBO 
lsokinetic trained 
6 
9 
10 
11 
12 
13 
14 
BL 
201 
92 
122 
94 
146 
145 
132 
2 
195 
117 
121 
91 
161 
136 
155 
7 
233 
119 
116 
95 
167 
152 
12 
193 
103 
111 
103 
175 
171 
mean 133.14 139.43 147.33 142.67 
sd 37.11 34.15 49.29 41.31 
sem 14.02 12.91 20.12 16.86 
lsokinetic trained 
6 
9 
10 
11 
12 
13 
14 
BL 2 7 12 
100 97.01 115.92 96.02 
100 127.17 129.35 111.96 
100 99.18 96.72 90.98 
100 96.81 101.06 109.57 
100 110.27 114.38 119.86 
100 93.79 104.83 117.93 
100 117.42 
mean 100 105.95 110.38 107.72 
ld 0 12.63 11.92 11.75 
oem 0 4.78 4.87 4.80 
Peak Torgye 
lsokinetic untrained 
BL 
2 
3 
4 
5 
6 
7 
91 
156 
117 
86 
96 
117 
122 
2 
102 
160 
136 
92 
114 
113 
129 
7 
113 
166 
156 
91 
96 
137 
12 
111 
155 
133 
96 
92 
mean 
ad 
oem 
112.71 120.86 126.83 117.40 
23.44 22.82 31.86 26.5 
8.86 8.63 13.01 11.83 
lsokinetic untrained 
BL 
1 
2 
3 
4 
5 
6 
7 
100 
100 
100 
100 
100 
100 
100 
2 7 12 
112.09 124.18 121.98 
102.5') 107.69 99.36 
116.21 133.33 113.68 
104.53 103.41 109.09 
116.33 97.96 93.88 
96.58 117.09 
105.74 
mean 
sd 
aem 
100.00 107.73 113.94 107.60 
0.00 7.42 13.39 11.2 
0.00 2.80 5.47 5.01 
lsokinetic untrained 
BL 
8 
9 
10 
11 
12 
13 
14 
218 
113 
94 
126 
187 
161 
138 
2 
209 
118 
114 
130 
186 
165 
167 
7 
221 
107 
129 
127 
195 
153 
12 
216 
102 
104 
129 
213 
146 
mean 
ad 
1-48.14 155.57 155.33 152.00 
43.43 36.04 44.10 51.86 
sem 16.41 
lsokinetic trained 
BL 
a 
9 
10 
11 
12 
13 
14 
mean 
ad 
.. m 
8l 
100 
100 
100 
100 
100 
100 
100 
100 
0 
0.00 
13.62 16.00 21.17 
2 7 12 
95.87 101.38 100.00 
104.42 94.69 90.27 
121.28 137.23 110.64 
103.17 100.79 102.38 
99.47 104.28 113.90 
102.48 95.03 90.68 
121.01 
106.82 105.57 101.31 
10.18 15.96 9.83 
3.85 6.52 4.01 
!sokln~lc 180dealtec 
CREATINE 
lsoklnetic trained 
BL 
1 72 
2 
72 
140 
102 
79 
85 
91 
94 
7 
98 
149 
96 
88 
108 
107 
12 
79 
133 
99 
80 
100 
2 140 
3 91 
4 69 
5 60 
6 84 
mean 
sd 
sem 
7 61 
88.14 94.71 107.67 98.20 
24.01 22.27 21.57 21.9 
9,07 6.42 6.80 9. 78 
lsokinetic trained 
1 
2 
3 
4 
5 
6 
7 
BL 2 7 12 
100 100.00 136.11 109.72 
100 100.00 106.43 95.00 
100 112.09 105.49 108.79 
100 114.49 127.54 115.94 
100 106.25 135.00 125.00 
100 108.33 127.38 
100 116.05 
mean 100.00 108.17 122.99 110.89 
sd 0.00 6.51 13,69 11.0 
sem 0 2.46 5.59 4.91 
PLACEBO 
lsokinetic trained 
8 
9 
10 
11 
12 
13 
14 
mean 
sd 
BL 
160 
57 
80 
60 
91 
102 
2 
149 
77 
81 
72 
111 
123 
106 111 
7 
175 
76 
83 
72 
117 
121 
12 
145 
80 
81 
76 
132 
132 
93.71 103.43 107.33 107.67 
34.87 28.18 39.20 31.80 
sem 13.18 10.65 16.00 12.98 
lsokinetic trained 
BL 2 7 12 
8 100 93.13 109.38 90.63 
135.09 133.33 140.35 9 100 
10 
11 
12 
13 
14 
mean 
od 
sem 
100 101.25 103.75 101.25 
100 120.00 120.00 126.67 
100 121.98 128.57 145.05 
100 120.59 118.63 129.41 
100 104.72 
100 113.82 118.94 122.23 
0 14.56 11.17 21.72 
0 5.50 4.56 8.87 
86 
lsokinetic untrained 
1 
2 
3 
4 
5 
6 
7 
BL 2 
58 
115 
76 
60 
77 
66 
66 
76 
119 
98 
72 
84 
79 
92 
7 
88 
132 
104 
77 
87 
96 
12 
77 
118 
100 
76 
84 
mean 74.29 88.57 97.33 91.00 
sd 19.35 16.18 19,28 17.9 
aem 7.31 6.12 7.86 8 
lsokinetic untrained 
2 
3 
4 
5 
6 
7 
BL 2 7 12 
100 131.03 151.72 132.76 
100 103.48 114.78 102.61 
100 128.95 136.84 131.58 
100 120.00 128.33 126.67 
100 109.09 112.99 109.09 
100 119.70 145.45 
100 135.29 
mean 100.00 121.08 131.69 120.54 
sd 0.00 11.69 15.90 13.8 
sem 0.00 4.42 6.49 6.17 
lsokinetic untrained 
8 
9 
10 
11 
12 
13 
BL 2 
156 
84 
65 
88 
127 
121 
184 
81 
81 
91 
123 
132 
7 
176 
79 
76 
89 
127 
132 
12 
174 
72 
71 
85 
141 
133 
14 106 
mean 106.83 111.14 113.17 112.67 
sd 33.62 30.60 39.06 42.74 
sem 13.72 11.57 15.94 17.45 
lsokinetic 
trained 
BL 2 7 12 
6 100 105.13 112.82 111.54 
9 100 96.43 94.05 85.71 
10 
11 
12 
13 
14 
100 124.62 116.92 109.23 
100 103.41 101.14 96.59 
100 96.85 100.00 111.02 
100 109.09 109.09 109.92 
mean 100 105.92 105.67 104.00 
sd 0 10.38 8.69 10.56 
sem 0.00 4.24 3.55 4.31 
!soklnetlc 240deafte:c 
CREATINE 
lsoklnetic trained 
BL 
1 60 
2 126 
3 71 
4 62 
5 76 
6 72 
7 87 
2 
57 
122 
79 
66 
83 
77 
106 
7 
80 
132 
80 
76 
104 
91 
12 
72 
122 
80 
69 
94 
mean 79.14 84.29 93.83 87.40 
sd 22.53 22.57 21.30 21.63 
sem 8.51 8.53 6.70 9.67 
lsokinetic trained 
1 
2 
3 
4 
5 
6 
7 
mean 
sd 
sem 
BL 2 7 12 
100 95 133.33 120 
100 96.83 104.76 96.83 
100 111.27 112.68 112.68 
100 106.45 122.58 111.29 
100 
100 
100 
100 
0 
0 
109.21 136.84 
106.94 126.39 
121.84 
106.79 122.76 
9.04 12.24 
3.42 5.00 
123.68 
112.90 
10.34 
4.62 
PLACEBO 
I saki netic trained 
BL 
B 145 
2 
138 
69 
77 
57 
99 
103 
92 
7 
151 
83 
71 
60 
102 
108 
12 
130 
64 
72 
64 
111 
114 
9 47 
10 64 
11 
12 
13 
14 
58 
92 
81 
79 
mean 80.86 90.71 95.83 92,50 
sd 32.13 26.63 32.54 29.17 
sem 12.14 10.06 13.29 11.91 
!so kinetic trained 
8 
9 
10 
11 
12 
13 
14 
BL 2 7 12 
100 95.17 104.14 89.66 
100 146.81 176.60 136.17 
100 120.31 110.94 112.50 
100 98.28 103.45 110.34 
100 107.61 110.87 120.65 
100 127.16 133.33 140.74 
100 116.46 
mean 100 115.97 123.22 118.34 
sd 0 17.85 28.32 18,69 
sem 0 6.745 11.561 7.629 
peak Tomue 
lsokinetic untrained 
BL 
1 52 
2 108 
3 68 
4 60 
5 71 
6 77 
7 58 
2 
•s 
103 
79 
64 
79 
66 
98 
7 
81 
114 
88 
76 
71 
92 
12 
73 
103 
83 
76 
73 
mean 
Sd 
sem 
70.57 79.14 87.00 81.60 
18.55 15.95 15.28 12.64 
7.01 6,03 6.24 5.65 
lsokinetic untrained 
BL 
1 
2 
3 
4 
5 
6 
7 
100 
100 
100 
100 
100 
100 
100 
100 
0 
2 7 12 
125 155.77 140.38 
95.37 105.56 95.37 
116.18 129.41 122.06 
106.67 126.67 126.67 
111.27 
85.71 
168.97 
118 
27 
100 102.82 
119.48 
123 117 
20 18 
mean 
sd 
sem 0.00 10.16 8.11 8.17 
lsokinetic untrained 
BL 
8 123 
9 66 
10 60 
11 
12 
13 
14 
mean 
sd 
77 
111 
104 
90.17 
25.96 
sem 10.60 
lsokinetic trained 
BL 
100 
100 
100 
100 
100 
100 
2 
133 
66 
81 
77 
113 
119 
81 
7 
145 
76 
72 
69 
110 
113 
12 
136 
60 
69 
71 
119 
111 
95.71 97.50 94.33 
25.49 30.26 31.58 
9.63 12.35 12.89 
2 7 12 
108.13 117.89 110.57 
100.00 115.15 90.91 
135.00 120.00 115.00 
100.00 89.61 92.21 
101.80 99.10 107.21 
114.42 108.65 106.73 
8 
9 
10 
11 
12 
13 
14 #DIVIO! #DIV/01 
mean 
sd 
sem 
87 
100 109.89 108.40 103.77 
0 13.53 11.91 9.92 
0.000 5.52.:\ 4.864 4.050 
Total Work Set On~ 
CREATINE 
Endurance Trained 
BL 2 
1 
2 
3 
4 
5 
6 
7 
1029 
2132 
1187 
679 
946 
1322 
1261 
666 
2275 
1222 
1309 
1243 
1455 
1447 
7 
1428 
2224 
1428 
1330 
1391 
607 
12 
1022 
2100 
1359 
1031 
1497 
mean 1222.57 1405.57 1434.67 1401.80 
sd 456.07 427.67 453.86 441.62 
sem 172.38 161.643 185.29 197.5 
PLACEBO 
Endurance Trained 
8 2029 1647 2123 
1177 
1020 
1036 
1818 
1764 
2119 
1170 
1189 
1130 
1771 
1901 
9 
10 
11 
12 
13 
14 
860 
942 
857 
1431 
1302 
1135 
1285 
1039 
900 
1584 
1824 
1428 
mean 1222.29 1415.29 1489.67 1546.67 
&d 418.64 366.55 470.81 435.17 
sem 158.23 138.54 192.21 177.66 
CREATINE 
Endurance Trained 
BL 2 7 12 
1 
2 
3 
4 
5 
6 
7 
100 
100 
100 
100 
100 
100 
100 
86.30 138.78 99.32 
106.71 104.32 98.50 
102.95 120.30 114.49 
192.78 195.88 151.64 
131.12 146.73 157.91 
110.06 
114.75 64.00 
mean 100.00 120.67 128.33 124.41 
sd o.oo 34.51 44.25 28.61 
sem 0 13.05 18.06 12.79 
PLACEBO 
Endurance Trained 
6 100 
9 100 
91.03 
149.42 
104.63 
136.86 
104.44 
136.05 
10 100 110.30 108.26 126.22 
11 100 105.02 120.89 131.86 
12 100 110.69 127.04 123.76 
13 100 140.09 135.48 146.01 
14 100 125.81 
mean 100.00 118.91 122.20 128.05 
sd 0.00 20.57 13.56 14.00 
sem 0 7.78 5.53 5.72 
68 
CREATINE 
Endurance Untrained 
2 
3 
4 
5 
6 
7 
BL 2 
1002 
1805 
1077 
846 
1345 
1391 
1298 
1066 
1945 
1475 
869 
1272 
1136 
1249 
7 
1168 
1996 
1467 
966 
1199 
669 
12 
1077 
1949 
1467 
1105 
1188 
mean 12ti2.29 1287.43 1250.83 1357.20 
sd 314.17 345.53 446.62 365.04 
sem 118.75 130.60 162.33 1'33.25 
PLACEBO 
Endurance Untrained 
a 1639 2194 
9 
10 
11 
12 
13 
14 
1222 
774 
1079 
1832 
1639 
713 
1243 
1079 
1224 
1936 
1695 
15aa 
2433 
1082 
1064 
1146 
2073 
1601 
2297 
965 
991 
1245 
1a89 
1593 
mean 1271.14 1565.57 1563.17 1496.67 
sd 444.07 409,65 581.78 530.18 
sem 167.84 154.83 237.51 216.44 
CREATINE 
Endurance Untrained 
BL 2 7 12 
1 
2 
3 
4 
5 
6 
7 
100 
100 
100 
100 
100 
100 
100 
108.39 116.57 107.49 
1C.7.76 110.58 107.9a 
136.95 136.21 136.21 
102.48 116.27 130.31 
94Sl 69.14 88.33 
81.67 
96.22 53.08 
mean 100.00 103.72 103.64 114.06 
sd 0.00 17.11 28.99 19.35 
sem 0.00 6.47 11.84 8.65 
PLACEBO 
Endurance Untrained 
a 100 133.86 
9 100 101.72 
148.44 
86.91 
140.15 
78.97 
10 100 139.41 137.47 12a.04 
11 100 113.44 106.21 115.38 
12 100 105.68 113.16 103.11 
13 100 103.42 97.6a 97.19 
14 100 222.72 
mean 100.00 131.46 114.98 110.47 
sd 0.00 42.93 23.64 22.07 
sem 0.00 16.23 9.85 9.01 
Jota! Work Set Two 
. __ ._.>·_~;·~~-~~~~:i~1~t~~;;--;_~~~TINE 
- -~- -~-, .,-_,-_,, __ --
-~:"--.:;;_ :~;>--'· -·c _,- Endurance Untrained 
,7,,, 12 BL 2 7 
1144 
1734 
1226 
805 
1101 
12 
1083 
1745 
1197 
875 
1166 
- - 1 957 
2 1931 
3 1083 
4 , 713 
5 889 
6 
7 
1158 
1189 
843 
1976 
1273 
1120 
1278 
1254 
1154 
1325 
1985 
1256 
1245 
1341 
1249 
1070 
1817 
1149 
1031 
1455 
mean 1125.71 1270.86 1125.71 1270.8B 
ad 392.04 345.89 392.04 345.69 
sem 148.18 130,66 160.05 154.60 
PLACEBO 
Endurance Trained 
8 1648 1536 1597 
932 
1035 
876 
1620 
1520 
1615 
903 
1106 
945 
1563 
1645 
9 
10 
11 
12 
13 
14 
700 
866 
727 
1540 
1287 
1026 
1017 
906 
740 
1519 
1736 
1176 
mean 1113.43 1232.86 1263,33 1298.17 
ad 384,48 371.15 351.10 346.88 
sem 145.32 
CREATINE 
· Endurance Trained 
BL 
1 
2 
3 
4 
5 
100 
100 
100 
100 
100 
140.28 143.34 142.43 
2 7 12 
88.09 138.45 111.81 
102.33 101.76 94.10 
119.76 118.16 108.09 
157.08 174.61 144.60 
146.84 154.32 167.43 
6 100 108.29 
7 100 97.06 105.05 
mean 100.00 117.06 132.06 125.21 
sd o.oo 25.91 28.94 30.00 
sem 0 9.79 11.82 13.42 
PLACEBO 
- Endurance Trained 
8 100 
9 100 
10 100 
11 100 
93.20 
145.29 
104.62 
101.79 
96.91 
133.14 
119.57 
120.50 
129.00 
127.71 
129.99 
12 100 98.64 105.19 101.49 
13 100 134.89 118.10 127.82 
14 10L 114.62 
mean 100.00 113.29 115.56 119.00 
•d 0.00 19,65 12.74 14.98 
aem 0 7.43 5.20 6.12 
89 
1 
2 
3 
4 
5 
6 
7 
1235 
1612 
938 
751 
1239 
1258 
1097 
1036 
1779 
1245 
765 
1211 
1024 
1187 1106 
mean 1161.43 1178.14 1161.43 1178.14 
ad 272.73 311.26 272.73 311.26 
aem 103.08 117.65 111.34 139.20 
PLACEBO 
Endurance Untrained 
B 1733 2008 
9 
10 
11 
12 
13 
14 
934 
799 
945 
1691 
1456 
679 
822 
1026 
1102 
1889 
1501 
1279 
1926 
803 
989 
983 
1980 
1431 
1898 
701 
959 
1005 
1649 
1459 
mean 1176,71 1375.29 1352.00 1278.50 
ad 438.74 445.74 509.79 461.31 
sem 165.83 168.47 208.12 188.33 
CREATINE 
Endurance Untrained 
BL 2 7 12 
1 
2 
3 
4 
5 
100 
100 
100 
100 
100 
83.89 92.63 86.07 
110.36 107.57 108.25 
132.73 130.70 127.61 
101.86 107.19 116.51 
97.74 88.86 94.11 
6 100 81.40 
7 100 108.20 100.82 
mean 100.00 102.31 104.63 106,51 
ad 0.00 17.43 14.85 16.73 
sem 0.00 6.59 6.06 7.48 
PLACEBO 
Endurance Untrained 
8 100 115.87 
9 
10 
11 
100 
100 
100 
88.01 
128.41 
116.61 
111.14 
85.97 
123.78 
104.02 
109.52 
75.05 
120.03 
106.35 
12 100 111.71 117.09 97.52 
13 100 103.09 98.28 100.21 
14 100 188.37 
mean 100.00 121.72 106.71 101.45 
•d 0.00 31.96 13.62 15.15 
sem 0.00 12.08 5.56 6.19 
Total Work Set Tb,[ee 
1 
2 
3 
4 
5 
6 
7 
887 
1530 
910 
763 
763 
980 
1073 
2 
839 
1643 
1113 
1024 
1192 
1074 
1059 
7 
1210 
1713 
1131 
1104 
1237 
993 
934 
1412 
955 
759 
1299 
mean 986.57 1134.86 1231.33 1071.80 
sd 264.13 248.74 251.23 272.87 
sem 99.63 94.015 102.56 122.03 
PLACEBO 
Endurance Trained 
8 1344 
9 541 
10 921 
11 666 
12 1463 
13 1182 
14 1048 
1149 
899 
827 
633 
1345 
1397 
961 
1323 
739 
1017 
747 
1239 
1280 
1340 
704 
1022 
805 
1451 
1328 
mean 1023.57 1030.14 1057.50 1108.33 
sd 339.78 279.53 265.49 310.58 
sem 128.43 105.65 108.39 126.79 
CREATINE 
Endurance Trairu~d 
BL 2 7 12 
1 
2 
3 
4 
5 
6 
7 
100 
100 
100 
100 
100 
100 
100 
94.59 136.41 105.30 
107.39 111.96 92.29 
122.31 124.29 104.95 
134.21 144.69 99.48 
156.23 162.12 170.25 
109.59 
98.70 92.54 
mean 100.00 117.57 128.67 114.45 
sd o.oo 21.78 24.65 31.03 
9 
10 
11 
12 
13 
14 
100 
100 
100 
100 
100 
100 
8.23 10.07 14.15 
166.17 136.60 130.13 
89.79 110.42 110.97 
95.05 112.16 120.87 
91.93 84.69 99.16 
118.19 108.29 112.35 
91.70 
mean 100.00 105.48 108.43 
17.17 
7.01 
112.20 
12.03 
4.91 
sd 0.00 28.79 
sem 0 10.88 
90 
Endurance Untrained 
2 
3 
4 
5 
6 
7 
BL 2 
1172 989 
1376 
797 
574 
1088 
1127 
903 
1515 
991 
607 
1083 
835 
991 
7 
1059 
1420 
980 
538 
980 
873 
12 
994 
1455 
930 
709 
1097 
mean 1005.29 1001.57 975.00 1037.00 
sd 266.69 275.09 285.13 273.50 
sem 100.798 103.975 116 41 122.31 
PLACEBO 
Endurance Untrained 
8 1829 1555 1435 
595 
1714 
552 
934 
934 
1489 
1233 
9 724 687 
10 
11 
12 
13 
14 
873 
777 
1526 
1322 
720 
1003 
930 
1814 
1285 
1079 
906 
812 
1687 
1365 
mean 1110.14 1193.29 1133.33 1142.67 
sd 447.79 38",'.18 423.31 422.02 
sem 169.25 146.34 172.82 172.29 
CREATINE 
Endur<.nce Untrained 
BL 2 7 12 
1 
2 
3 
4 
5 
6 
7 
100 
100 
100 
100 
100 
100 
100 
84.39 90.36 84.81 
110.10 103.20 105.74 
124.34 122.96 116.69 
105.75 93.73 123.52 
99.54 90.07 100.83 
74.09 
109.75 96.68 
mean 100,00 101.14 99,50 108.32 
sd 0.00 16.97 12.47 14.97 
sem 0.00 6.42 5.09 6.69 
PLACEBO 
Endurance Untrained 
8 100 85.02 78.46 93.71 
9 
10 
11 
12 
13 
14 
100 
100 
100 
100 
100 
100 
94.89 82.18 76.24 
114.89 103.78 106.99 
119.69 104.50 120.21 
118.87 110.55 97.58 
97.20 103.25 93.27 
149.86 
mean 100.00 111.49 97.12 
13.33 
5.44 
98.00 
14.75 
8.02 
sd 0.00 21.55 
•em o.oo 8.14 
Total Work Set four 
End,uran,ce Trained 
1 
2 
3 
4 
5 
6 
7 
BL 2 
862 747 
1520 1532 
839 965 
700 1009 
805 1226 
883 956 
987 875 
7 
1205 
1451 
1035 
1017 
1125 
823 
1315 
668 
675 
1234 
942.29 1044.29 1109.33 980.40 
268.93 259.24 210.79 278.93 
101.64 97.99 86.06 124.74 
PLACEBO 
Endurance Trained 
8 1231 
9 423 
10 807 
11 589 
12 
13 
14 
1401 
1069 
1094 
1082 
801 
856 
622 
1246 
1311 
907 
1219 
640 
913 
656 
1456 
1172 
1257 
643 
1001 
725 
1380 
1214 
mean 944.86 975.00 1009.33 1036.67 
ad 352.51 248.82 328.77 300.42 
aem 133.24 94.04 134.22 122.64 
CREATINE 
Endurance Trained 
BL 2 7 12 
1 
2 
3 
4 
5 
100 86.66 139.79 93.97 
100 100.79 95.46 86.51 
100 115.02 123.36 103.46 
100 144.14 145.29 96.43 
100 152.30 139.75 153.29 
6 100 108.27 
7 100 88.65 83.:;8 
mean 100.00 113.69 121.17 106.73 
sd 0.00 25.73 25.95 26.72 
sem 0 9.73 
PLACEBO 
Endurance Trained 
8 100 87.90 
9 100 189.36 
10.59 11.95 
99.03 102.11 
151.30 152.01 
10 
11 
100 106.07 113.14 124.04 
100 105.60 111.38 123.09 
12 100 88.94 103.93 98.50 
13 100 122.64 109.64 113.56 
14 100 82.91 
mean 100.00 111.92 114.73 116,89 
ad 0.00 36.82 18.66 19.32 
sem o 13.92 7.62 7.88 
- -~ ---
91 
2 
3 
4 
5 
6 
7 
BL 
1067 
1271 
735 
503 
1180 
1077 
831 
2 
997 
1321 
858 
534 
1062 
761 
850 
944 
1269 
626 
471 
1028 
757 
964 
1302 
791 
631 
1055 
mean 952.00 911.86 882.50 948.60 
sd 272.62 248.14 269.30 256.01 
sem 103.04 93.79 109.94 114.49 
PLACEBO 
Endurance Untrained 
8 1460 1406 
9 
10 
11 
12 
13 
14 
644 
951 
696 
1653 
1193 
681 
628 
962 
826 
1610 
1173 
944 
1288 
480 
930 
776 
1527 
1272 
1304 
506 
913 
839 
1368 
1127 
mean 1039.71 1081.29 1045.50 1009.50 
sd 405.70 339.79 386.71 322.79 
sem 153.34 128.43 157.87 131.78 
CREATINE 
Endurance Untrained 
BL 2 7 12 
1 
2 
3 
4 
5 
100 
100 
100 
100 
100 
93.44 88.47 90.35 
103.93 99.84 102.44 
116.73 112.38 107.62 
106.16 93.64 125.45 
90.00 87.12 89.41 
6 100 70.66 
7 100 102.29 91.10 
mean 100.00 97.60 95.42 103.05 
sd 0.00 14.73 9.45 14.75 
sem 0,00 5.57 
PLACEBO 
Endurance Untrained 
8 100 96.30 
9 100 97.52 
3.86 
88.22 
74.53 
6,60 
89.32 
78.57 
10 
11 
100 
100 
103.26 97.79 96.00 
118.68 111.49 120.55 
12 100 97.40 92.38 82.76 
13 100 98.32 106.62 94.47 
14 100 138.62 
mean 100.00 107.16 95.17 93.61 
sd 0.00 15.93 13.32 14.79 
sem 0.00 6.02 5.44 6.04 
2 
3 
4 
5 
6 
7 
Total Wofk Set Fin 
BL 
814 
2 
671 
1443 1413 
784 839 
603 951 
781 1146 
854 937 
904 750 
7 
1115 
1368 
942 
850 
1077 
807 
818 
1296 
856 
638 
1210 
mean 883.29 958.14 1026.50 963.20 
sd 264.02 252.54 206.83 278.97 
sem 99.79 95.45 
PLACEBO 
84.36 124.76 
Endurance Trained 
8 1125 1083 
9 
10 
11 
12 
13 
14 
458 719 
823 854 
595 515 
1436 1281 
963 1241 
1157 820 
1059 
641 
929 
606 
1463 
1135 
1162 
598 
926 
708 
1319 
1235 
mean 936.71 930.43 972.17 991.33 
sd 339.81 282.24 322.67 295.00 
sem 128.44 106.68 131.73 120.43 
CREATINE 
Endurance Trained 
1 
2 
3 
4 
5 
6 
7 
BL 2 7 12 
100 8243 136.98 100.49 
100 97.92 94.80 89.81 
100 107.02 120.15 109.18 
100 157.71 140.96 105.47 
100 148.73 137.90 154.93 
100 109.72 
100 82.96 89.27 
mean 100.00 112.07 120.01 111.98 
sd 0.00 29.56 22.92 25.09 
sem 0 
PLACEBO 
11.17 9.36 11.22 
Endurance Trained 
8 100 96.27 
9 100 156.99 
10 100 103.77 
94.13 
139.96 
112.88 
103.29 
130.57 
112.52 
11 
12 
13 
14 
100 86.55 101.85 118.99 
100 89.21 101.88 91.85 
100 128.87 117.86 128.25 
100 70.87 
mean 100.00 104.85 111.43 114.24 
sd 0.00 29.16 16.37 14.90 
sem 0 11.02 6.68 6,08 
• ' , - _c ; ~ ,; .•,- '' '.-.-
1 
2 
3 
4 
5 
6 
7 
1130 
1229 
754 
503 
1083 
1018 
757 
2 
970 
1258 
805 
506 
1033 
767 
797 
1197 
776 
479 
1001 
689 
1296 
767 
607 
1013 
mean 924.86 676.57 852.67 921.00 
sd 259.36 237.86 255.96 260.48 
sem 98.03 89.90 104.50 116.49 
PLACEBO 
Endurance Untrained 
8 1439 1361 
9 
10 
11 
12 
13 
14 
587 
933 
700 
1692 
1134 
696 
633 
983 
819 
1566 
1157 
902 
1197 
465 
928 
735 
1471 
1215 
1279 
424 
888 
800 
1357 
1136 
mean 1025.66 1060.14 1001.83 980.67 
sd 416.80 323.35 365.65 348.10 
sem 157.54 122.22 149.27 142.11 
CREATINE 
Endurance Untrained 
BL 2 7 12 
1 
2 
3 
4 
5 
6 
7 
100 
100 
100 
100 
100 
100 
100 
85.84 86.19 81.59 
102.36 97.40 105.45 
106.76 102.92 101.72 
100.60 95.23 120.68 
95.38 92.43 93.54 
75.34 
105.28 91.02 
mean 100.00 95.94 94.20 100.60 
sd 0.00 11.50 5.74 14.48 
sem 0.00 
PLACEBO 
4.35 2.34 6.48 
Endurance Untrained 
8 100 94.58 
9 
10 
100 
100 
107.84 
105.36 
83.18 
79.22 
99.46 
88.88 
72.23 
95.18 
11 100 117.00 105.00 114.29 
12 100 92.55 86.94 80.20 
13 100.00 102.03 107.14 100.18 
14 100.00 129.60 
mean 100.00 106.99 93.49 91.83 
sd 0.00 12.92 11.90 14.92 
sem 0.00 4.88 4.86 6.09 
BL 2 7 12 Untrained BL 2 
5058 
7818 
5374 
3281 
7 
5289 
7616 
5275 
3279 
12 
5040 
7147 
5152 
3927 
4549 3988 6273 4654 5606 
2 
3 
4 
8556 8839 8721 7940 7293 
4783 5412 5592 
3531 5413 5546 
5187 
5132 
5 4166 6083 6171 6695 
mean 5117 5947 6460.6 5921.6 mean 
ad 1979.9 1788.2 1305.7 1364.0 ad 
sem 885.46 799.73 583.93 610.00 sem 
PLACEBO 
4301 
3179 
5935 5661 5309 5519 
5262.8 5438.4 5353.6 5477 
1577.9 1621.4 1535.8 1401.2 
705.64 725.10 686.83 626.65 
Trained 
8 
BL 2.00 7.00 12.00 
7493.0 
Untrained BL 2.00 
8524.0 
7.00 
8279.00 
12.00 
8490.0 7377.0 6697.0 7321.0 
9 2982.0 4721.0 4129.0 4018.0 
10 4359.0 4482.0 4914.0 5244.0 
11 3434.0 3410.0 3921.0 4313.0 
12 7071.0 6975.0 7596.0 7484.0 
13 5703.0 7509.0 6871.0 7323.0 
mean 5154.3 5632.3 5792.0 5979.1 mean 
ad 1856.1 1646.2 1660.9 1644.6 ad 
oem 757.76 672.08 678.08 671.44 sem 
CREATINE 
8100.00 
4111.00 4013.0 3405.00 3148.0 
4330.00 5073.0 4818.00 4685.0 
4197.00 4901.0 4452.00 4823.0 
8394.00 8815.0 8741.00 7752.0 
6544.00 6811.0 6884.10 6548.0 
5946.00 6356.1 6096.50 5907.6 
2001.38 2010.3 2189.06 2038.0 
817.06 820.70 893.68 832.01 
Trained BL 2.00 7.00 12.00 Untrained BL 2.00 7.00 12.00 
1 100.00 87.67 137.90 102.31 100.00 90.22 94.35 89.90 
2 100.00 103.31 101.93 92.80 100.00 107.20 104.43 106.23 
3 100.00 113.15 116.91 108.45 100.00 124.95 122.65 119.79 
4 100.00 153.30 157.07 145.34 100.00 103.21 103.15 123.53 
5 100.00 146.02 148.13 160.71 100.00 95.38 89.45 92.99 
mean 100.00 120.69 132.39 121.92 mean 100.00 104.19 102.60 106.49 
sd 0.00 28.08 22.66 29.44 sd 0.00 13.36 12.71 15.20 
sem 0.00 12.56 10.13 13.17 sem 0.00 5.97 5.68 6.80 
PLACEBO 
Trained 8L 2.00 7.00 12.00 Untrained BL 2.00 7.00 12.00 
8 100.00 90.78 09.24 101.57 100.00 105.23 102.21 104.81 
9 10tl.OO 158.32 138.46 134.74 100.00 97.62 82.83 76.58 
10 100.00 102.82 112.73 120 30 100.00 117.16 111.27 108.20 
11 100.00 99.30 114.18 125.60 100.00 116.77 106.08 114.92 
12 100.00 98.64 107.42 105.84 100.00 105.02 104.13 92.35 
13 
mean 
sd 
••m 
100.00 131.67 120.48 128.41 
100.00 113.59 115.42 119.41 mean 
0.00 26.04 13.35 13.09 sd 
0.00 11.65 5.97 5.86 aem 
100.00 104.08 105.20 
100.00 107.65 101.95 
0.00 7.74 9.85 
0.00 3.46 4.40 
100.06 
99.49 
13.55 
8.08 
APPENDIXF 
(Knee Flexor Muscle Function Data) 
94 
CREATINE 
; .li10melrlc trained (75deg) 
1 
2 
3 
4 
5 
8 
7 
BL 2 
62 65 
75 84 
41 
76 
71 
56 
81 
62 
65 
68 
60 
96 
mean 86.29 71.43 
ad 13.76 13.39 
aem 5.20 5.06 
Isometric trained (75deg) 
1 
2 
3 
4 
5 
6 
7 
BL 2 
100 
100 
100 
100 
100 
100 
100 
105 
112 
151 
86 
00 
103 
119 
7 
83 
98 
58 
102 
72 
83 
82.67 
16.32 
6.66 
7 
134 
131 
141 
134 
101 
102 
12 
63 
102 
62 
83 
72 
80,4 
14.91 
6,87 
12 
134 
136 
151 
109 
101 
mean 
od 
oem 
100 110.19 124.01 128.34 
0 21.00 17.46 20.52 
0 7.94 7.13 9.18 
PLACEBO 
Isometric trained (75deg) 
BL 2 
8 117 118 
9 45 41 
10 47 56 
11 58 81 
12 73 95 
13 77 76 
14 65 68 
mean 68.86 78.43 
ad 24.43 25.29 
sem 9.23 9.56 
Isometric trained (75deg) 
BL 2 
8 100 101 
9 100 91 
10 100 119 
11 100 140 
12 100 130 
13 100 99 
14 100 105 
mean 100.00 112.03 
0.00 17.97 
sem o 8.79 
7 
99 
41 
56 
83 
77 
64 
73.33 
2UO 
8.61 
7 
65 
91 
119 
143 
105 
109 
108.76 
20.94 
8.55 
12 
114 
42 
50 
89 
71 
85 
75.17 
26.83 
10.87 
12 
97 
93 
106 
153 
97 
110 
109.71 
22.35 
9.13 
' ,_,, '· __ ,._ .-_ 
95 
Isometric untrained (75deg) 
1 
2 
3 
4 
5 
8 
Bl 2 
85 
87 
42 
62 
57 
47 
61 
98 
49 
66 
64 
68 
7 
69 
106 
49 
81 
85 
7808769 
mean 62.86 70.71 80.17 
ad 16.34 16.51 19,86 
sem 6.18 8.24 8.11 
Isometric untrained (75deg) 
Bl 2 7 
1 
2 
3 
4 
5 
8 
7 
100 
100 
100 
100 
100 
100 
100 
94 
113 
117 
110 
112 
145 
109 
137 
124 
117 
131 
149 
86 
12 . 
84 
111 
57 
71 
79 
80.40 
19.92 
8.91 
12 
129 
128 
138 
115 
139 
mean 100 114.08 123.96 129.13 
ad 0 15.31 21.55 9.34 
sem 0.00 5.79 8.80 4.18 
Isometric untrained {75deg) 
BL 2 7 
8 
9 
10 
11 
12 
13 
14 
89 
45 
58 
64 
92 
64 
89 
107 
81 
52 
80 
73 
75 
99 
mean 74.43 78.14 
sd 1&.57 19.51 
sem 7.02 7.38 
Isometric trained (75deg) 
8 
9 
10 
11 
12 
Bl 2 
100 
100 
100 
100 
100 
120 
69 
58 
90 
82 
13 100 84 
14 100 111 
mean 100.00 87.81) 
sd 0.00 21.93 
sem 0 8.29 
110 
50 
80 
81 
au 
75 
76.00 
20.64 
8.43 
7 
124 
56 
67 
91 
90 
84 
85.39 
23.19 
9.47 
77 
57 
82 
80 
76 
75 
70.40 
10.21 
4.17 
12 
87 
64 
70 
90 
85 
79.10 
11.47 
5.13 
trained (60deg) 
BL 2 7 BL 2 7 12 
1 71 75 89 1 88 60 92 98 
2 81 91 115 114 2 98 114 121 132 
3 50 80 66 73 3 28 53 53 62 
4 81 58 110 94 4 58 79 104 71 
5 73 75 81 84 5 54 65 94 88 
6 56 89 6 42 64 
7 96 115 103 7 83 89 91 
mean 72.57 83.00 94.00 93.00 61.29 74.86 92.50 91.40 
ld 15.69 18.21 18.74 15.59 23.75 21.07 22.40 26.34 
10m 5.93 6.88 7.65 6.97 sem 8.98 7.96 9.15 11.78 
Isometric trained {60deg) Isometric untrained (60deg) 
BL 2 7 12 BL 2 7 12 
1 100 106 125 141 1 100 91 139 148 
2 100 112 142 141 2 100 116 123 135 
3 100 160 132 146 3 100 1R9 189 221 
4 100 69 136 116 4 100 136 179 133 
5 100 103 111 115 5 100 120 174 163 
6 100 159 6 100 152 
7 100 120 7 100 107 
mean 100 118.37 129.22 131.74 mean 100 130.39 161.11 160.07 
sd 0 32.27 11.86 14.93 sd 0 32.61 28.20 36.39 
sem 0 12.20 5.30 6.68 sem 0 12.32 12.61 16.21 
- ---~· -,:- - PLACEBO 
Isometric trained (60deg} Isometric untrained (60deg) 
BL 2 7 12 BL 2 7 12 
8 122 145 117 138 8 81 133 13S i26 
9 50 49 53 52 9 54 60 54 60 
10 86 68 66 65 10 73 73 73 73 
11 69 88 95 100 11 17 85 85 91 
12 87 113 94 102 12 99 85 76 94 
13 95 80 96 95 13 89 85 76 89 
14 68 80 14 102 122 
mea mea 
n 79.57 89.00 86,83 92.00 n 82.14 91.86 83.33 88.80 
sd 23.80 31.40 23.20 30.39 sd 16.48 26.18 27.75 24.97 
12.40 9.895 10.19 
sem 8.9943 11.87 9.471 1 sem 6.228 7 11.33 6 
Isometric trained (60deg) Isometric untrained (60deg) 
BL 2 7 12 BL 2 7 12 
8 100 119 96 113 8 100 164 168 156 
9 100 98 106 104 9 100 111 100 111 
10 100 103 100 98 10 100 100 100 100 
11 100 128 138 145 11 100 110 110 118 
12 100 130 108 117 12 100 86 77 95 
13 100 84 101 100 13 100 96 85 100 
14 100 118 14 100 120 
mea 111.3 108.1 112.9 mea 100.0 112.3 106.7 113.3 
n 100.00 1 1 6 n 0 8 4 0 
sd 0.00 16.76 15.12 17.31 sd 0.00 25,44 32.25 22.38 
sem 0 6.33 6.17 7.07 sem 0 9.62 13.16 9.14 
96 
97 
.. )soklnetlc 60degluC 
1 
2 
.3 
4 
5 
BL 
68 
76 
84 
75 
60 
2 
81 
87 
75 
56 
61 
58 71 
88 95 
69,86 75.14 
10.56 13.86 
7 
79 
123 
88 
83 
71 
100 
90,67 
18.55 
100 
111 
106 
83 
60 
sem 3.99 5.24 7.57 
92.00 
20.8 
9.29 
lsoklnetic trained 
BL 2 7 12 
100 119.12 116.18 147.06 
100 114.47 161.84 146.05 
100 117.19 137.50 165.63 
100 74.67 110.67 110.67 
100 101.67 118.33 100.00 
100 122.41 
100 107.95 113.64 
100.00 108.21 126.36 133.88 
0.00 16.37 19.80 27.5 
sem 0 
PLACEBO 
lsokinetic trained 
6.19 8.08 12.28 
BL 
8 127 
9 46 
10 94 
11 76 
12 107 
13 100 
14 66 
2 
151 
47 
92 
100 
119 
91 
84 
7 
142 
47 
75 
94 
116 
85 
12 
153 
52 
79 
102 
126 
98 
mean 88.29 97.71 93.50 101.67 
ad 26.99 31.98 33.26 35.27 
sem 10.2 12.09 13.58 14.40 
lsoklnetic trained 
8 
9 
10 
11 
12 
13 
14 
mean 
ld 
sem 
BL 2 7 12 
100 118.90 111.81 120.47 
100 102.17 102.17 113.04 
100 97.87 79.79 84.04 
100 131.58 123.68 134.21 
100 111.21 110.28 117.76 
100 
100 
100 
0 
0 
91.00 85.00 98.00 
123.53 
110.90 102.12 111.25 
14.68 16.84 17.74 
5,55 6.87 7.24 
98 
1 
2 
3 
4 
5 
92 
65 
61 
62 
49 
111 
83 
76 
61 
6 57 91 
7 75 87 
mean 66.57 79.71 
sd 13.05 20.32 
aem 4.93 7.68 
lsoklnetfc untrained 
BL 2 
83 
114 
108 
85 
83 
100 
95.17 
13.38 
5.46 
7 
84 
117 
107 
76 
73 
91.40 
19.6 
8.74 
12 
1 
2 
3 
4 
5 
6 
7 
100 90.74 153.70 155.56 
100 120.65 123.91 127.17 
100 127.69 163.08 164.62 
100 124.59 139.34 124.59 
100 98.39 133.87 117.74 
100 159.65 
100 116.00 133.33 
mean 100.00 119.67 141.21 137.94 
sd 0.00 22.33 14.51 20.8 
sem 0 8.44 5.92 9.28 
lsokinetlc untrained 
BL 
8 122 
9 53 
10 80 
11 84 
12 110 
13 92 
14 89 
2 
146 
62 
B4 
92 
95 
89 
115 
7 
152 
58 
91 
91 
103 
84 
12 
167 
69 
91 
89 
119 
85 
mean 90.00 97.57 96.50 103.33 
sd 22.11 26.49 31.05 35.13 
sem 8.36 10,01 12.68 14.34 
lsokinetic trai~ed 
BL 2 7 12 
8 
9 
10 
11 
12 
13 
14 
mean 
sd 
sem 
100 119.67 124.59 136.89 
100 116.9'; 109.43 130.19 
100 105.00 113.75 113.75 
100 109.52 108.33 105.95 
100 
100 
100 
100 
0 
0 
86.36 93.64 108.18 
96.74 
129.21 
109.07 
14.52 
5.49 
91.30 
106.84 
12.55 
5.12 
92.39 
114.56 
16.43 
6.71 
trained 
BL 2 7 12 BL 2 7 12 
1 58 68 60 76 1 49 68 76 84 
2 66 77 88 83 2 73 85 87 83 
3 65 72 69 79 3 58 71 68 72 .· •.. 
4 50 50 75 69 4 56 72 81 73 
5 54 50 53 50 5 54 60 66 65 
6 49 52 6 27 65 
7 54 72 69 7 69 75 77 
mean 56.57 63.00 69.00 71.40 mean 55.14 70.86 75.60 75.40 
sd 6.78 11.85 13.55 13.0 sd 15.00 7.95 8.79 8.0 
sem 2.56 4.48 5.53 5.82 sem 5.67 3.00 3.59 3.59 
lsokinetic trained lsokinetic untrained 
BL 2 7 12 BL 2 7 12 
1 100 117.24 103.45 131.03 1 100 138.78 155.10 171.43 
2 100 116.67 133.33 125.76 2 100 116.44 119.18 113.70 
3 100 110.77 106.15 121.54 3 100 122.41 117.24 124.14 
4 100 100.00 150.00 136.00 4 100 128.57 144.64 130.36 
5 100 92.59 98.15 92.59 5 100 111.11 122.22 120.37 
6 100 106.12 6 100 240.74 
7 1on 133.33 127.78 7 100 108.70 111.59 
-mean 100.00 110.96 118.22 121.78 mean 100.00 138.11 131.68 132.00 
- --sd o.oo 13.25 22.39 17.4 sd 0.00 46.43 17.11 22.9 
sem 0.00 5.01 9.14 7.80 sem 0.00 17.55 6.98 10.22 
PLACEBO 
lsoklnetic trained lsokinetic untrained 
BL 2 7 12 BL 2 7 12 
8 92 108 96 102 8 98 96 100 111 
9 45 39 39 45 9 49 49 42 54 
10 57 66 52 53 10 53 56 62 68 
11 31 68 69 68 11 61 58 64 64 
12 73 91 85 91 12 84 76 77 81 
13 77 79 68 68 13 73 73 69 68 
14 54 66 14 56 77 
mean 61.29 73.86 68.17 71.17 mean 67.71 69.29 69.00 74.33 
sd 20.74 21.83 20.84 21.81 sd 18.07 16.06 19.12 19.95 
sem 7.84 8.25 8.51 8.90 sem 6.83 6.07 7.81 8.14 
lsoklnetic trained lsokinetic trained 
BL 2 7 12 BL 2 7 12 
8 100 117.39 104.35 110.87 8 100 97.96 102.04 113.27 
9 100 86.67 86.67 100.00 9 100 100.00 85.71 110.20 
10 100 115.79 91.23 92.98 10 100 105.66 116.98 128.30 
11 100 219.35 222.58 219.35 11 100 95.08 104.92 104.92 
12 100 124.66 116.44 124.66 12 100 90.48 91.67 96.43 
13 100 102.60 88.31 88.31 13 100 100.00 94.52 93.15 
14 100 122.22 14 100 137.50 
mean 100 126.95 118.26 122.70 mean 100 103.81 99.31 107.71 
sd 0 42.81 52.36 49.13 sd 0 15.58 11.11 12.71 
som o.oo 16.18 21.37 20.06 sem 0.00 5.89 4.54 5.19 
99 
. "_;; '-~l~<-~~;·::~ \' :·-,,;-
_;_g~~i1:~~:ti~ ~R:;~~~etjc 240dea{sec 
· ~~~;~J:L lsokinetic ~~ined 
2 
_:;; kf,, 1 56 68 
,,,,, 2 68 64 
ot>'', cc' 3 60 60 
' ,,g,', 4 45 49 
·-~·:~~k- '_,-:,-__ 5 56 45 
--~--"'-- 6 35 39 
, __ < 
7 54 69 
mean 53.43 56.29 
sd 10.64 11.91 
sem 4.02 4.50 
lsokinetlc trained 
1 
2 
3 
4 
5 
6 
7 
mean 
sd 
BL 
100 
100 
100 
100 
100 
100 
100 
100 
0 
sem 0.00 
PLACEBO 
2 
121.43 
94.12 
100.00 
108.89 
80.36 
111.43 
127.78 
106.29 
16.25 
6.14 
lsokinetic trained 
BL 2 
8 83 99 
9 43 42 
10 57 60 
11 37 61 
12 69 84 
13 65 56 
14 47 66 
mean 57.29 66.86 
sd 16.22 18.91 
sem 6.13 7.15 
lsokinetic trained 
BL 2 
8 100 
9 100 
10 100 
11 100 
12 100 
13 100 
14 100 
mean 100 
sd o 
sem 0.00 
119.28 
97.67 
105.26 
164.86 
121.74 
86.15 
140.43 
119.34 
26.74 
10.11 
7 
57 
89 
61 
64 
50 
61 
63.67 
13.32 
5.44 
7 
101.79 
130.88 
101.67 
142.22 
89.29 
112.96 
113.13 
19.95 
8.14 
7 
87 
39 
52 
57 
72 
62 
61.50 
16.60 
6.78 
7 
104.82 
90.70 
91.23 
154.05 
104.35 
95.38 
106.76 
23.98 
9.79 
12 
76 
77 
68 
66 
45 
66.40 
12.90 
5.77 
12 
135.71 
113.24 
113.33 
146.67 
80.36 
117.86 
25.48 
11.40 
12 
80 
37 
53 
56 
79 
62 
61.17 
16.44 
6.71 
12 
96.39 
86.05 
92.98 
151.35 
114.49 
95.38 
106.11 
24.09 
9.83 
100 
BL 2 
1 56 65 
2 73 77 
3 53' 62 
4 61 69 
5 52 53 
6 38 46 
7 65 71 
mean 56.86 &3.29 
sd 11.10 10.72 
sem 4.19 4.05 
lsoklnetic untrained 
BL 2 
1 100 116.07 
2 100 105.48 
3 100 116.98 
4 100 113.11 
5 100 101.92 
6 100 121.05 
7 100 109.23 
mean 100 111.98 
sd o 6.79 
sem 0.00 2.56 
lsokinetic untrained 
BL 2 
8 84 75 
9 42 43 
10 52 47 
11 50 54 
12 68 62 
13 69 62 
14 49 68 
mean 59.14 58.71 
sd 14.86 11.40 
sem 5.62 4.31 
isokinetic trained 
8 
9 
10 
11 
12 
13 
14 
mean 
sd 
BL 
100 
100 
100 
100 
100 
100 
100 
100 
0 
sem o.oo 
2 
89.29 
102.38 
90.38 
108.00 
91.18 
89.86 
138.78 
101.41 
18.02 
6.81 
7 
71 
is 
65 
62 
58 
79 
68.33 
8.04 
3.28 
7 
126.79 
102.74 
122.64 
101.64 
111.54 
121.54 
114.48 
10.76 
4.39 
7 
85 
47 
61 
53 
71 
61 
63.00 
13.51 
5.51 
7 
101.19 
111.90 
117.31 
106.00 
104.41 
88.41 
104.87 
9.90 
4.04 
65.40 
10.69 
4.78 
12 
141.07 
102.74 
107.55 
95.08 
111.54 
111.60 
17.58 
7.86 
12 
98 
49 
64 
57 
71 
64 
67.17 
16.85 
6.88 
12 
116.67 
116.67 
123.08 
114.00 
104.41 
92.75 
111.26 
10.91 
4.45 
' 
- 'C.'"- .~.:. -; -> , .,. 
~4!~lt~~~~:ElW~~m w set one 
-:,~~;:'C:/·.:: ,. ~ Endurance Trained 
-<~~~tf~--~-: ;-- BL 2 7 
669 
1055 
1131 
1021 
692 
12 
1155 
1105 
1125 
1041 
766 
'''Iif'i:i' 1 1043 1126 
J1'£iE ! ~~1 ~~6: 
--~_o.:~~T,':;:·:-f_ 5 636 860 
~"""''-"'-
._,--' 
6 600 627 
7 515 1051 
mean 803.00 994.57 
sd 206.91 128.62 
709 
912.63 
185.33 
sem 78.20 46.69 75.66 
1042.60 
149.41 
66,62 
PLACEBO 
Endurance Trained 
6 1351 1036 
9 579 557 
10 763 759 
11 754 1056 
12 1062 1397 
13 923 976 
14 909 669 
mean 905.86 950.29 
sd 249.36 263.54 
sem 94.26 99.61 
CREATINE 
Endurance Trained 
BL 2 
100 106.15 
100 113.53 
100 110.09 
100 136.06 
976 
536 
772 
1025 
1109 
917 
669.17 
206.66 
94.37 
7 
63.32 
111.52 
110.77 
154.70 
1246 
447 
677 
945 
1196 
909 
903.33 
304.73 
124.41 
1 
2 
3 
4 
5 
6 
7 
100 135.22 106.61 
100 103.36 
12 
110.74 
116.91 
110.19 
157.73 
123.58 
100 204.06 137.67 
mean 100.00 130.07 117.80 123.83 
19.71 
8.82 
sd 0.00 35.13 24.96 
sem 0.00 13.28 10.19 
PLACEBO 
Endurance Trained 
6 100 76.66 
9 100 96.20 
10 100 99.46 
11 100 140.05 
12 100 131.54 
13 100 105.96 
14 100 95.60 
mean 100.00 106.50 
sd 0.00 22.05 
sem 0.00 8.33 
72.24 92.23 
92.57 77.20 
101.16 68.73 
135.94 125.33 
104.43 112.62 
99.35 98.48 
100.95 99.10 
20.66 17.36 
8.43 7.08 
101 
CREATINE 
Endurance Untrained 
BL 2 
1 766 652 
2 1197 1326 
3 926 1014 
4 636 960 
5 934 845 
6 690 1136 
7 694 773 
mean 892.14 989.71 
sd 161.01 192.96 
sem 60.86 72.93 
PLACEBO 
Endurance Untrained 
8 1374 1226 
9 385 747 
10 513 569 
11 777 925 
12 1161 1147 
13 1045 974 
14 995 1299 
mean 892.86 986.71 
sd 354.17 258.23 
sem 133.86 97.60 
CREATINE 
Endurance Untrained 
BL 2 
1 100 111.23 
2 100 110.94 
3 100 109.50 
4 100 116.95 
5 100 90.47 
6 100 164.64 
7 100 86.47 
mean 100.00 112.88 
sd 0.00 25.54 
sem 0.00 9,65 
PLACEBO 
Endurance Untrained 
6 100 69.23 
9 100 194.03 
10 100 114.81 
11 100 119.05 
12 100 96.79 
13 100 93.21 
14 100 130.55 
mean 100.00 119.95 
sd o.oo 35.90 
sem 0.00 13.57 
7 
922 
1193 
913 
639 
955 
873 
949.17 
126.07 
51.47 
1462 
616 
662 
814 
1146 
679 
933.17 
327.96 
133.89 
7 
120.37 
99.67 
98.60 
100.12 
102.25 
97.65 
103.11 
8.60 
3.51 
107.66 
160.00 
129.04 
104.76 
98.71 
84.11 
114.08 
26.60 
10.94 
12 
1003 
1333 
691 
720 
979 
985.20 
223.90 
100.13 
1323 
622 
711 
663 
1069 
616 
904.00 
256.02 
104.52 
12 
130.94 
111.36 
96.22 
85.92 
104.82 
105.65 
16.96 
7.59 
96.29 
161.56 
138.60 
113.64 
92.08 
78.09 
113,37 
31.46 
12.64 
Bl 2 7 12 Bl 2 7 12 
1 936 1021 823 1031 1 900 773 . 86~ 848 
2 873 ~ 876 839 2 1039 1 69 646 979 
3 875 '1044 932 975 .. 3 814 80 758 761 
4 711 BIB 933 ~· 4 757 926 839 704 
5 605 772 656 '"" 5 919 868 83!> 884 
6 67B B3B . . 6 na 1 1223 
7 . 597 862 "559 7 730 757 691 
[mean [753.57 tmean 1842.43 [931.86 
[sd )139.20 )105.09 · [sd i 115.09 . iT'f5:09)189.96_ 
\i;iic~.64 . 39.72 1 56.86 1 47.00 ·I~ 1 43.50 71.80 (46.98T84.95 
. -· f- . ·--1-- - t- . . 
8 105< 
1 
906 720 941 8 ~T'f*5 1242 957 
9 656. 490 403 391 -- 9 309 607 530 522-
10 583 62 607 541 10 449 454 561 599 
11 715 . 926 883 853 11 732 ~ ~ 698 
12 ;:) . We~ IJR- .i* -if ~~~ I ~ t;W ~~e3 
14 801 644 .14 928 1149 
~ 1791.5'. ".7
0
2
0
6.,17
0
1742.00 !mean 786.2 1801.50 76117 
[sd 1 ,..... [sd [306.15[291.91 [192.38 
~~~,53 I 80.54 I 81.43 I 93.21 Iii~ 
1
115.7 1113.47 78.54 
~~~B~VL~1~2;_ l-Y 12 .. Bl i 2 7 12 
1 100 · 1 87.93 :110.15 .1 too B5.B91 96.56 94.22, 
2 100 I 95.65 1100.341 96.11 2 100 12.5' I 81.42 94:23 
3 100 [119.31[106.51[R11_1~1.43 t- 100 99.14 I 93.12 93.49 
1--!, .L100 ... l~.~. 1_1_~!B_ .. 10C )110.83 93.0! 
I • : _1()() [127.60 i 108.43 .. _ _5_. I 100 11-i: 9~44 .. ~5[ 9~0J .. B~6[ 9~65 .. 1~9 
6 100 6 100 ~ 
7 101 144.39 93.63 7 100 03.70 I 94.52 
[mean [104.68 [mean [100.00[111.96[94.55[94.23 
[sd o.oo 15.27 15.12 1 21.99 [sd 0.00 26.51 9.56 1.22 
[sem 0.00 .. 5.77 6.17 9.83 · [sem 0.00 I 10.02 3.90 0.54 
[sem 0.00 7.64 · 9.62 ·· 7.98 [sem 0.00 13.79 12.99 I 13.71 
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CREATINE 
Endurance Trained Endurance Untrained 
BL 2 7 12 BL 2 7 12 
1 895 1007 721 993 1 876 716 754 736 
2 697 761 792 679 2 900 923 723 789 
3 810 892 784 876 3 700 740 633 656 
4 770 692 713 1033 4 785 826 812 622 
5 589 636 570 620 5 755 734 765 808 
6 583 738 6 765 1123 
7 446 773 471 7 613 655 571 
mean 684.29 784.86 685.17 840.20 mean 770.57 816.71 709.67 722.20 
sd 154.83 124.04 133.65 184.58 sd 98.45 160.32 90.31 81.30 
sem 58.52 46.88 54.56 82.55 sem 37.21 60.60 36.87 36.36 
PLACEBO PLACEBO 
Endurance Trained Endurance Untrained 
8 881 725 503 914 8 1287 997 1010 972 
9 640 404 301 316 9 274 484 393 419 
10 567 584 507 422 10 450 399 536 548 
11 589 860 633 715 11 606 682 629 641 
12 743 921 640 856 12 862 929 894 979 
13 724 697 704 670 13 804 702 656 613 
14 702 534 14 942 1022 
mean 692.29 675.00 548.00 648.83 mean 746.43 745.00 686.33 695.33 
sd 106.76 182.27 144.73 236.77 sd 336.13 247.57 228.36 230.13 
sem 40.35 68.89 59.09 96.66 sem 127.05 93.57 93.23 93.95 
CREATINE CREATINE 
Endurance Trained Endurance Untrained 
BL 2 7 12 BL 2 7 12 
1 100 111.96 80.56 110.95 1 100 81.74 86.07 84.02 
2 100 109.18 113.63 97.42 2 100 102.56 80.33 87.67 
3 100 110.12 96.79 108.15 3 100 105.71 90,43 93.71 
4 100 89.87 100.39 134.16 4 100 105.22 103.44 79.24 
5 100 107.98 96.77 105.26 5 100 97.22 101.32 107.02 
6 100 126.59 6 100 146.80 
7 100 173.32 105.61 7 100 106.85 93.15 
mean 100.00 118.43 98.96 111.19 mean 100.00 106.69 92.46 90.33 
sd 0.00 26.46 11.D4 13.80 sd 0.00 19.75 8.85 10.72 
sem 0.00 10.00 4.51 6.17 sem 0.00 7.47 3.61 4.80 
PLACEBO PLACEBO 
Endurance Trained Endurance Untrained 
8 100 82.29 57.09 103.75 8 100 77.47 78.48 75.52 
9 100 63.13 47.03 49.38 9 100 176.64 143.43 152.92 
10 100 103.00 89.42 74.43 10 100 88.67 119.11 121.78 
11 100 146.01 107.47 121.39 11 100 112.54 103.80 105.78 
12 100 123.96 86.14 115.21 12 100 107.77 103.71 113.57 
13 100 96.27 97.24 92.54 13 100 87.31 81.59 76.24 
14 100 76.07 14 100 108.49 
mean 100.00 98.67 80.73 92.78 rna an 100.00 108.41 105.02 107.64 
sd 0.00 28.72 23.61 27.D7 sd 0.00 32.83 24.21 29.35 
sem 0.00 10.85 9.64 11.05 sem 0.00 12.41 9.88 11.98 
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CREATINE 
Endurance Trained Endurance Untrained 
BL 2 7 12 BL 2 7 12 
1 923 997 679 888 1 873 644 702 711 
2 711 708 674 633 2 841 890 639 651 
3 758 852 742 784 3 701 693 594 635 
4 709 772 694 951 4 744 774 765 564 
5 560 605 530 576 5 724 685 698 704 
6 648 803 6 674 1028 
7 395 740 415 7 613 640 571 
mean 672.00 782.43 622.33 766.40 mean 738.57 764.86 661.50 653.00 
sd 164.89 122.63 123.98 160.64 sd 91.43 145.33 73.40 59.61 
sem 62.32 46.35 50.61 71.84 sem 34.56 54.93 29.97 26.66 
PLACEBO PLACEBO 
Endurance Trained Endurance Untrained 
8 942 793 544 808 8 1172 1024 941 856 
9 605 354 216 271 9 366 437 359 391 
10 541 542 522 415 10 466 423 477 498 
11 572 842 628 618 11 502 603 609 605 
12 673 875 777 777 12 898 845 880 968 
13 583 628 602 601 13 728 678 598 576 
14 659 454 14 869 946 
mean 653.57 641.14 548.17 581.67 mean 714.43 708.00 644.00 649.00 
sd 135.56 202.31 185.83 207.54 sd 287.34 238.70 226.43 219.65 
sem 51.24 76.46 75.87 84.73 sem 108.60 90.22 92.44 89.67 
CREATINE CREATINE 
Endurance Trained Endurance Untrained 
BL 2 7 12 BL 2 7 12 
1 100 108.02 73.56 96.21 1 100 73.77 80.41 81.44 
2 100 99.58 94.80 89.03 2 100 105.83 75.98 77.41 
3 100 112.40 97.89 103.43 3 100 98.86 84.74 90.58 
4 100 108.89 97.88 134.13 4 100 104.03 102.82 75.81 
5 100 108.04 94.64 102.86 5 100 94.61 96.41 97.24 
6 100 123.92 6 100 152.52 
7 100 187.34 105.06 7 100 104.40 93.15 
mean 100.00 121.17 93.97 105.13 mean 100.00 104.86 88.92 84.50 
sd 0.00 30.07 10.69 17.23 sd 0.00 23.74 10.24 9.14 
sem o.oo 11.37 4.36 7.71 sem 0.00 8.97 4.18 4.09 
PLACEBO PLACEBO 
Endurance Trained Endurance Untrained 
8 100 84.18 57.75 85.77 8 100 87.37 80.29 73.04 
9 100 58.51 35.70 44.79 9 100 119.40 98.09 106.83 
10 100 100.18 96.49 76.71 10 100 90.77 102.36 106.87 
11 100 147.20 109.79 108.04 11 100 120.12 121.31 120.52 
12 100 130.01 115.45 115.45 12 100 94.10 98.00 107.80 
13 100 107.72 103.26 103.09 13 100 93.13 82.14 79.12 
14 100 68.89 14 100 108.86 
mean 100.00 99.53 86.41 88.98 mean 100.00 101.96 97.03 99.03 
sd 0.00 31.95 32.15 25.99 sd 0.00 13.90 14.98 18.62 
sem 0.00 12.08 13.13 10.61 sem o.oo 5.25 6.12 7.60 
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CREATINE 
Endurance Trained Endurance Untrained 
BL 2 7 12 BL 2 7 12 
1 919 989 648 891 1 922 636 679 626 
2 697 674 597 620 2 796 823 552 636 
3 717 786 701 789 3 655 637 551 583 
4 735 796 705 937 4 704 759 625 526 
5 553 599 480 609 5 755 677 641 746 
6 690 753 6 663 1055 
7 50£ 792 469 7 445 584 564 
mean 688.14 769.86 600.00 769.20 mean 705.71 738.71 602.00 623.40 
sd 134.07 121.19 104.98 151.09 sd 147.04 161.35 53.90 81.11 
sem 50.67 45.81 42.86 67.57 sem 55.58 60.98 22.00 36.27 
PLACEBO PLACEBO 
Endurance Trained Endurance Untrained 
8 861 728 553 766 8 1045 1043 903 934 
9 594 370 176 260 9 343 438 359 401 
10 518 540 521 376 10 468 428 479 491 
11 551 743 532 700 11 484 652 574 576 
12 690 868 816 706 12 896 909 873 914 
13 603 618 597 601 13 709 640 610 618 
14 659 453 14 849 898 
mean 642.29 617.14 532.50 568.17 mean 684.86 715.43 633.00 655.67 
sd 120.55 175.61 206.00 204.20 sd 260.14 240.62 216.01 220.88 
sem 45.56 66.37 84.10 83.36 sem 98.32 90.95 88.19 90.17 
CREATINE CREATINE 
Endurance Trained Endurance Untrained 
BL 2 7 12 BL 2 7 12 
1 100 107.62 70.51 96.95 1 100 68.98 73.64 67.90 
2 100 96.70 85.65 88.95 2 100 103.39 69.35 79.90 
3 100 109.62 97.77 110.04 3 100 97.25 84.12 89.01 
4 100 108.30 95.92 127.48 4 100 1 07.81 88.78 74.72 
5 100 108.32 86.80 110.13 5 100 89.67 84.90 98.81 
6 100 109.13 6 100 159.13 
7 100 156.52 92.69 7 100 131.24 126.74 
mean 100.00 113.74 88.22 106.71 mean 100.00 108.21 87.92 82.07 
sd 0.00 19.39 9.93 14.70 sd 0.00 29.29 20.40 12.12 
sem 0.00 7.33 4.05 6.58 sem o.oo 11.07 8.33 5.42 
PLACEBO PLACEBO 
Endurance Trained Endurance Untrained 
8 100 82.63 62.77 86.95 8 100 99.81 86.41 89.38 
9 100 62.29 29.63 43.77 9 100 127.70 104.66 116.91 
10 100 104.25 100.58 72.59 10 100 91.45 102.35 104.91 
11 100 134.85 96.55 127.04 11 100 134.71 118.60 119.01 
12 100 125.80 118.26 102.32 12 100 101.45 97.43 102.01 
13 100 102.49 99.00 99.67 13 100 90.27 86.04 87.17 
14 100 68.74 14 100 105.77 
mean 100,00 97.29 84.47 88.72 mean 100.00 107.31 99.25 103.23 
sd 0.00 27.55 32.36 28.49 sd 0.00 17.33 12.30 13.34 
sem 0.00 10.41 13.21 11.63 sem o.oo 6.55 5.02 5.45 
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CREATINE 
Trained BL 2 7 12 Untrained BL 2 7 12 
1 4716 5137 3740 4958 4337 36~1 3826 3924 
2 3904 4052 3994 3877 4773 5133 3953 4388 
3 4181 4698 4290 4549 3796 3891 3449 3526 
4 3585 3976 4126 5062 3828 4265 3880 3136 
5 2943 3472 2728 3316 4087 3809 3894 4121 
mean 3865.8 4267 3775.6 4352.4 4164.2 4143.8 3800,4 3819 
sd 662.2 653.0 619.2 743.1 404.7 600.5 201.6 494.6 
sem 296.15 292.03 276,93 332.35 sem 180.98 268.56 90.14 221.17 
PLACEBO 
Trained BL 2 7 12 Untrained BL 2 7 12 
8 5109 4188 3296 4675 6006 5505 5578 5042 
9 3074 2175 1632 1645 1677 2713 2257 2355 
10 2972 3046 2929 2431 2366 2313 2715 2847 
11 3181 4427 3701 3831 3101 3606 3331 3403 
12 4109 5167 4295 4487 4854 4926 4815 4933 
13 3624 3739 3611 3555 3207 3791 3492 3411 
mean 3678.2 3790.3 3244.0 3437.3 3535.2 3809.0 3698.0 3665.2 
sd 818.1 1060.6 910.9 1185.5 1610.0 1233,3 1265.1 1097.5 
sem 334.00 433.00 371.87 484.00 sem 657.27 503.48 516.46 448.05 
CREATINE 
Trained BL 2 7 12 Untrained BL 2 7 12 
1 100 108.93 79.30 105.13 100 83.49 88.22 90.48 
2 100 103.79 102.31 99.31 100 107.54 82.82 91.93 
3 100 112.37 102.61 108.80 100 102.50 90.86 92.89 
4 100 110.91 115.09 141.20 100 111.42 101.36 81.92 
5 100 117.97 92.69 112.67 100 93.20 95.28 100.83 
mean 100 110.79 98.40 113.42 100 99.63 91.71 91.61 
sd 0.0 5.2 13.3 16.3 0.0 11.3 7.0 6.7 
sem 0.00 2.31 5.95 7.28 sem 0.00 5.06 3.14 3.02 
PLACEBO 
Trained BL 2 7 12 Untrained BL 2 7 12 
8 100 81.97 64.51 91.51 100 91.66 92.87 83.95 
9 100 70.75 53.09 53.51 100 161.78 134.59 140.43 
10 100 102.49 98.55 81.80 100 97.76 114.75 120.33 
11 100 139.17 116.35 120.43 100 116.29 107.42 109.74 
12 100 125.75 104.53 109.20 100 101.48 99.20 101.63 
13 i\.10 103.17 99.64 98.10 100 118.21 108.89 106.36 
mean 100.0 103.9 89.4 92.4 100.0 114.5 109.6 110,4 
sd 0.0 25.7 24.8 23.3 0.0 25.4 14.5 18.9 
sem 0.00 10.49 10.13 9.53 sem 0.00 10.37 5.90 7.73 
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